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TARGETING BREAST CANCER WITH BACTERIOPHAGE ASSOCIATED 
SILICON PARTICLES 
  
Srimeenakshi Srinivasan, Ph.D.* 
Supervisory Professor: Mauro Ferrari, Ph.D. 
 
Nanoparticle based therapeutics have been successfully used in the treatment of 
breast cancer. Development of nanovectors targeted to cancer cells or elements in the tumor 
microenvironment has been pursued to improve their site specific accumulation while 
reducing the non-specific delivery to normal tissues. However, addition of targeting ligands 
to the surface of nanovectors while maintaining their payload carrying potential is generally 
challenging. Therefore, there is a critical need to develop surface decoration strategies that 
allow for effective combination of targeting and payload delivery to the tumor.  
In this study, we propose a novel strategy for covering the surface of mesoporous 
silicon particles (S1MP) with targeting entities (bacteriophage) and gold nanoparticles 
(AuNP) while maintaining their payload carrying potential. Retention of payload carrying 
potential after the formation of BASP was demonstrated by loading different types of 
nanoparticles and macromolecules into the porous structure of S1MP. Additionally, the 
BASP displayed enhanced near infrared (NIR) absorbance that could be used for thermal 
ablation of the tumor as well as for in vivo monitoring using NIR surface enhanced Raman 
spectroscopy (NIR-SERS). In vitro targeting studies under static and shear flow conditions, 
as experienced in healthy microvasculature (100s-1), did not display significant targeting 
 vii 
 
efficiency of the CRKL targeted BASP. However, in shear rates relevant to the tumor 
microvasculature (10s-1), CRKL targeted BASP demonstrated 2-fold higher adhesion than 
S1MP to endothelial cells. These results were further exaggerated in in vivo conditions 
evidenced by intravital microscopy studies that showed up to 4 fold increase in the number of 
CRKL targeted BASP accumulating in the tumor vasculature compared to both S1MP and 
fd-tet non-targeted BASP. In vivo experiments also showed that BASP maintain their 
integrity following intravenous administration in mice and a 3-fold higher tumor 
accumulation than S1MP. Furthermore, treatment of breast tumor bearing mice with 
Abraxane loaded CRKL targeted BASP showed significantly reduced tumor growth in 
comparison to Abraxane or Abraxane loaded S1MP controls. Overall, this study 
demonstrates a simple and efficient strategy to target S1MP to breast cancer while 
maintaining their ability to carry large amounts of therapeutic payload. 
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CHAPTER 1: INTRODUCTION 
1.1 Breast cancer as a disease 
1.1.1 Pathophysiology 
The structure of the female breast is complex – comprising of (i) milk producing 
glands called lobules, (ii) ducts that carry milk from the lobules to the nipple and (iii) stroma 
that is made up of connective tissue, blood vessels and lymphatic vessels (Figure 1). Breast 
cancer is a disease where cells in the breast divide and grow without normal control. 
Depending on the location of the tumor, breast cancer can be lobular or ductal. These can be 
further divided into invasive and non-invasive carcinoma. About 70 – 80% of breast cancers 
are invasive ductal carcinomas. A third type of cancer is inflammatory breast cancer where 
the cancer cells block the lymph vessels, causing redness and warmth in the breast. Breast 
cancers are staged according to the TNM staging given by the American Joint Committee on 
Cancer (AJCC), based on their tumor size (T), nodal involvement and size (N) and metastatic 
involvement (M). This staging is very important in deciding the overall prognosis and the 
treatment of patients. Staging is done by a combination of physical examinations, various 
imaging tests, such as x-ray and computed tomography (CT) scan, blood tests and biopsies. 
In spite of advancements in detection techniques, breast cancer is the second leading cause of 
cancer related deaths in women in the US [1]. Early detection techniques and primary tumor 
treatments have markedly improved, however occurrence of distant metastasis and the 
inefficiency in their treatment make breast cancer the second leading cause of cancer related 
death in women in the U.S. [2].  
  
Figure 1: Schematics of breast cancer.
carcinoma. Adapted from the website of the National Cancer Institute 
(http://www.cancer.gov)   
1.1.2 Current therapeutic strategies for 
Depending on the TNM
in breast cancer includes surgery, radiation therapy, cytotoxic chemotherapy, hormone 
therapy and targeted molecular therapy
localized and has defined margins. 
the chance of recurrence in the breast or nearby lymph nodes
treatment when distant metastase
drugs either injected intravenously or given orally. The most common c
chemotherapeutic drugs used
(Paclitaxel) and platinum compounds 
doxorubicin (Doxil®)[4] and paclitaxel (Abraxane
2 
 Top row, lobular carcinoma and bottom row, ductal 
breast cancer 
 staging the schedule of therapy varies. The first line therapy 
 [3]. Surgery is usually prescribed when the tumor is 
Radiation therapy typically follows surgery
. Radiation is also the choice of 
s are seen. Chemotherapy is the treatment using 
 in breast cancer include anthracyclines (Doxorubicin), taxane
(Cisplatin) among others. Nanoparticle formulations of 
TM)[5] have also been successfully used in 
 to help lower 
cytotoxic 
ytotoxic 
s 
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the clinic for breast cancer therapy for many years now. Molecularly targeted therapeutic 
agents based on identified biomarkers are also used in combination with chemotherapeutic 
drugs. Examples include Herceptin® [6], a monoclonal antibody which interferes with 
overexpressed HER2 thereby inhibiting the cell proliferation caused by HER2. Another 
example is Lapatinib [7], a synthetic tyrosine kinase inhibitor that affects HER2 and 
epidermal growth factor receptor (EGFR) pathways. Table 1 lists therapeutic agents that are 
either clinically approved or under clinical trials. 
Therapeutic agents currently used in the clinic 
Chemical name Brand name Type Mode of action 
Trastuzumab Herceptin Monoclonal antibody HER-2/neu inhibitor 
Lapatinib Tykerb Drug Tyrosine kinase 
inhibitor 
Bevacizumab Avastin Monoclonal antibody Angiogenesis inhibitor 
Pertuzumab Perjeta Monoclonal antibody Prevents HER-2 
dimerization 
Everolimus Afinitor Drug mTOR inhibitor 
T-DM1 Kadcyla Monoclonal antibody/drug 
conjugate 
HER-2/neu inhibitor 
Antimitotic 
Therapeutic agents under clinical trials 
Name Phase Type Mode of action 
AUY922 Phase I,II Drug Heat Shock Protein 90 
inhibitor 
BEZ235 Phase I Drug PI3 kinase inhibitor 
BGT226 Phase I,II Drug PI3 kinase/mTOR 
inhibitor 
PF-04691502 Phase II Drug PI3 kinase/mTOR 
inhibitor 
XL765 Phase I,II Drug PI3 kinase/mTOR 
inhibitor 
BKM120 Phase I Drug PI3 kinase inhibitor 
GDC-0941 Phase I,II Drug PI3 kinase inhibitor 
MK-2206 Phase I Drug Akt inhibitor 
CDX-011  Phase II Monoclonal antibody/drug 
conjugate 
Antimitotic 
Table 1: List of therapeutic agents used in clinic/under clinical trials for breast cancer. 
Source www.clinicaltrials.gov.  
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1.1.3 Disavantages of conventional chemotherapy 
Conventional chemotherapeutic as well as targeted antibody molecules, when injected 
into the blood stream, either get degraded or sequestered by the reticuloendothelial system 
(RES). Further, owing to their small size, they easily penetrate the endothelial barrier and 
non-specifically enter the tissue space in any organ, leading to undesired cytotoxic side 
effects in uninvolved organs, such as hypersensitivity reactions (Paclitaxel) and 
cardiotoxicity (Doxorubicin) [8]. Thus, the probability of a drug molecule reaching the target 
site is as low as 1 in 100,000 molecules [9]. Due to the inefficiency of conventional 
chemotherapy and the low quality of life experienced by patients, better alternatives had to 
be identified. Nanomedicine showed promising results in improving both the quality and 
efficiency of treatments. 
1.2 Nanomedicine research and its application in breast cancer 
1.2.1 What is nanomedicine? 
Nanomedicine is the field of medicine that employs materials that are themselves or 
have components in the nanoscale, i.e. 1 to 1000nm. Both designing nanovectors for delivery 
of diagnostic and therapeutic agents as well as precise patterning of surfaces are subfields of 
nanomedicine [10]. Owing to the small size of these nanovectors, their interactions with 
biological systems at the molecular level are unique. Various nanovectors have been 
developed for use in cancer detection, diagnosis, imaging, treatment and disease monitoring. 
Nanovectors may be made from a spectrum of materials including lipids, phospholipids, 
dextran, carbon, silica, gold and silver [11], among others. Nanovector design has evolved 
over the years. The first generation of nanovectors were generally composed of a single class 
of particles (liposome, micelle, etc.) encapsulating a payload and accumulates in the tumor 
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due to enhanced permeation and retention (EPR) effect. The accumulation of such 
nanovectors in the tumor cells solely depend on their size [12]. The second generation of 
nanovectors encompasses delivery systems with added functionalities such as decoration of 
the nanovector surface with targeting moieties for active targeting and active/triggered 
release of payload at site of action [13]. Active targeting refers to the biomolecular 
recognition of cancer cell surface epitopes by recognition moieties on nanovector surfaces, 
such as antibodies, peptides or aptamers. Contemporary nanovectors are more complex and 
may employ  multiple classes of nanoparticles that are designed to perform distinct functions 
[13]. 
1.2.2 Advantages of nanovectors 
Unlike conventional chemotherapeutic drugs that are small molecules able to cross 
most endothelial barriers and reach the tissue beyond, nanovectors are large enough to avoid 
transmigration across normal endothelial barrier, but small enough to “leak” through 
fenestrations in the tumor vasculature and concentrate in the tumor tissue [10]. The ability of 
nanovectors to carry substantial amounts of therapeutic agent to the intended site is the major 
advantage over conventional cytotoxic/immunotargeted drugs, whereas the chance of a drug 
molecule reaching the tumor site is only 1 in 100,000 [10]. Another important advantage of 
nanovectors is their protective effect on the payload. The first barrier faced by intravenously 
injected drugs or siRNA or monoclonal antibodies is degradation. Encapsulation of the 
therapeutic agent in nanoparticles protects the active ingredient from such degradation, until 
they reach the disease site. This protection of drug indirectly translates to minimized 
interaction with normal tissues by virtue of size exclusion, thereby reducing unwanted side 
effects [8]. While intravenously administered free drug molecules get cleared from the 
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plasma either through the kidneys (hydrophilic molecules [14]) or through enzymatic 
metabolism in the liver (lipophilic molecules [15]), larger nanovectors (< 15 nm is the renal 
cut off [16]) do not get cleared by the renal system quickly as well as protect the active 
ingredient from enzymatic metabolism in the liver [17] . 
Many cancer chemotherapies rely on combination therapy, i.e. co-administration or 
sequential administration of multiple drugs, to overcome resistance and enhance the 
therapeutic efficacy. Multidrug encapsulation in nanoparticles has been demonstrated in 
various studies. Examples include doxorubicin loaded liposomes covered by layers of siRNA 
loaded poly-L-lysine films for the treatment of triple-negative breast cancer [18] and 
liposome encapsulated formulation of irinotecan and floxuridine for solid tumors [19]. This 
enhances the probability of 2 individual drugs reaching the same tumor site than when 
injected as free drug molecules [20].  
Formulation of nanoparticles can be altered to facilitate sequential release of drugs, if 
required. For example, the biodegradability of most materials used in the design of 
nanovectors, facilitate the release of the payload after degradation [21]. Other approaches 
include pH [22] and/or heat triggered [23] release of the active ingredient.  Nanoparticles are 
also beneficial due to their ability to penetrate cell membranes through receptor mediated 
endocytosis and lysosomal escape after endocytosis [24] thereby facilitating the release of 
drug directly inside the cells to enhance therapeutic effect.  
1.2.3 Nanotechnology in breast cancer 
Nanotechnology has made major contributions in breast cancer. Liposomal 
doxorubicin (Doxil®) was the first and representative nanovector that was approved for 
clinical use about two decades ago for Kaposi’s sarcoma [25]. Now they have also been used 
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in breast [26; 27] and ovarian cancer [28]. Nanoparticle albumin-bound paclitaxel, Abraxane, 
is another drug that has been approved for metatstatic breast cancer therapy [29; 30]. There 
are a few more nanovectors that are undergoing clinical trials for the treatment of breast 
cancer, such as paclitaxel incorporating micelles [31] and TNF-bound colloidal gold 
(Aurmine) [32; 33].  A list of nanovectors clinically approved/under clinical trials for use in 
breast cancer therapy are summarized in Table 2. Other nanoparticle formulations for breast 
cancer therapy that are still under pre-clinical evaluation include polymeric nanoparticle 
encapsulating tamoxifen [34], adenovirus type 5 E1A (against ERBB2) [35], p53 loaded 
nanoparticles [36] and nanoparticle-siRNA complexes directed to Ras [37].  
Nanoparticles have also been used for various other applications in breast cancer. Use 
of nanoparticles such as carbon nanotubes (CNT) [38], silicon nanowires (SiNW) [39], 
quantum dots [40], gold nanoparticles [41] and silver nanoparticles ex vivo has allowed rapid, 
label free, multiplexed detection of biomarkers at ultralow detection limits, which can 
contribute substantially to the early diagnosis and accurate prognosis of cancers [42]. In vivo 
tumor imaging using nanoparticles is also a very fast developing field of research. Magnetic 
nanoparticles such as superparamagnetic iron oxide nanoparticles (SPION) and bismuth 
sulfide nanoparticles [43] are attractive systems as they can be used as MRI contrast agents. 
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Therapeutic agent Type Clinical phase Indication 
Doxorubicin Liposomal Approved and in 
clinical trials 
Breast cancer 
Magnetic targeted 
beads 
Phase I,II Liver metastasis 
Paclitaxel Abraxane Approved and in 
clinical trials 
Breast cancer 
Polymeric micelles Phase IV Breast cancer 
Synthetic 
phospholipids and 
cholesterol 
Phase II Breast cancer 
siRNA against PLK1 
gene product 
Stable Nucleid Acid 
Lipid Particles 
(SNALP) 
Phase I Liver metastasis 
Tumor Necrosis Factor Colloidal gold Phase 0 Breast cancer 
Cytarabine Liposomal Phase II CNS metastasis 
Annamycin Liposomal Phase II Anthracycline 
resistant breast 
cancer 
Docetaxel Liposomal Phase I Advanced breast 
cancer 
Table 2: List of nanovectors clinically approved/under clinical trials for the use of breast 
cancer therapy. Source www.clinicaltrials.gov.  
 
1.2.4 Limitations of currently investigated nanovectors 
Inspite of all the advantages described in Chapter 1.2.2, other than the few 
nanovectors described above, no new nanovectors have been approved for clinical use in the 
last two decades. There are various challenges that need to be addressed to enable the design 
of more efficient nanovectors. Delivery of nanovectors to the tumor tissue faces various 
obstacles from the site of injection until they reach the tumor tissue. Some of the barriers 
include but are not limited to enzymatic degradation, recognition and sequestration by 
reticulo-endothelial system (RES) and vascular endothelium (Figure 2). 
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Figure 2: Sequential biological barriers experienced by a drug molecule or nanoparticle 
when in circulation from the point of injection to the tumor site. Reproduced with permission 
from [44]. 
 
Each of these barriers has to be overcome before the nanovector can efficiently 
deliver therapeutics to the tumor cells. Many strategies have been put forward for 
overcoming some of these barriers [45; 46]. For example, molecular targets on tumor cells 
have been used to advantage for homing nanoparticles to the tumor site. Various peptide 
[47], antibodies [48; 49], oligonucleotides [50; 51] and other molecules [52; 53] have been 
conjugated to the surface of nanoparticles to enhance tumor specific accumulation. However, 
the limited access of nanoparticles to the blood vessel walls diminishes the effectiveness of 
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the targeting moiety in enhancing nanoparticle accumulation in the tumor [54]. Another 
technique used for increasing tumor accumulation is the conjugation of polyethylene glycol 
(PEG) to the surface of nanoparticles, to delay or avoid their sequestration by the RES 
organs. PEGylation prevents opsonization of the particles by immune cells, thereby 
increasing the circulation time and chance for the nanovectors to accumulate in the tumor 
[55]. PEGylation, however, masks targeting moieties conjugated on nanoparticles, thus 
negating the advantage of targeting moieties [56]. Thus, we can understand that adding 
functionalities to a single nanoparticle doesn’t solve the limitations. There is an emerging 
requirement for a multimodular nanoassembly, in which different components with 
individual and distinct functions act in a synergistic manner to circumvent each barrier 
sequentially.  
1.3 Multistage nanovectors 
1.3.1 Rational design 
A nanovector must be able to travel from the site of injection to the tumor site after 
bypassing sequential biobarriers mentioned earlier. A single nanoparticle would not be able 
to overcome all of the barriers successfully. Thus far, tumor specific accumulation of 
nanoparticles has relied on EPR effect. This limits the versatility of nanoparticles in various 
ways. First, the size of the particles is limited to the size of fenestrations present in the tumor 
vasculature (380 – 780 nm) [57]. Most current nanovectors are approximately in this size 
range (100 – 300 nm) and hence have been shown to extravasate through the fenestrations 
and accumulate in the tumor mass [57]. Even this is not a constant feature as the size of the 
fenestrations depends on the stage and type of tumors [58]. To address these issues, the 
concept of multistage vectors (MSV) was developed [59]. MSV were designed as vasculature 
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targeting nanovectors (Stage 1 MicroParticles, S1MP) that can release smaller payloads 
(Stage 2 NanoParticles, S2NP) containing imaging/therapeutic agents. They were engineered 
to overcome biological barriers by decoupling the multiple functions typically required by 
nanovectors and distributing them onto multiple stages [21]. 
Most of the nanoparticles that are currently in the clinics or under investigation are 
synthesized using bottom-up fabrication or self-assembly technique and hence acquire an 
energetically favorable spherical shape. However, when in circulation, it has been shown that 
the size and shape of particles affect their trajectory as well as specific (ligand-receptor type) 
and non-specific (van der Waals, electrostatic and steric) interactions with the vessel wall 
[60].  The size of the particles dictates their interaction with the red blood cells in the 
circulation. Smaller nanoparticles (<500nm) stay in the middle of blood vessels because they 
“fit” in the pockets between RBCs, while larger particles (micron sized) get pushed to the 
“cell-free” zone of blood vessels by RBCs [54]. This process of “margination” has two main 
functions: (1) it facilitates the “drift” of particles from the center of the vessel to the vessel 
wall thereby (2) allowing higher probability of interaction of the particles with the 
endothelial cells to “identify and bind” to molecular targets [60]. Spherical particles require 
an external force, such as gravitational or magnetic, to induce a lateral shift/margination 
towards the vessel wall [61]. On the other hand, non-spherical particles, depending on their 
orientation in the circulation and the forces exerted by the blood on them, easily marginate 
without the requirement of additional forces. The velocity with which the particles marginate 
is directly proportional to their aspect ratio. Thus, spherical particles, with aspect ratio of 1 
have the least propensity of marginating while discs (aspect ratio of infinity) have the highest 
chance and velocity of marginating to the vessel walls [60]. 
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Another important aspect affected by the shape and size of the particles is their ability 
to adhere to the vessel wall, following margination. As mentioned before, the interaction with 
the vessel wall can be specific due to ligand-receptor interactions or non-specific, caused by 
various physical forces. In both cases, the stronger these interactions are, the more force will 
be required to dislodge the particles. Non-spherical particles, again, depending on their 
orientation on the vessel wall, can have higher surface area interacting – both specific and 
non-specific. This means, that the force required to dislodge the particle will be more than if 
a spherical particle of similar volumes were to interact with the surface [60].  
1.3.2 S1MP  
Based on the above, our group rationally designed non-spherical S1MP that are made 
of porous silicon S1MP. Porous silicon is a biocompatible and biodegradable [62; 63; 64] 
material that has been investigated increasingly for its application in drug delivery [62; 65; 
66; 67]. S1MP is manufactured by a combination of photolithography and electrochemical 
etching in hydrofluoric acid. The etching offers tunable pore size and porosity rendering it 
suitable for drug loading and conjugation of multiple targeting ligands [68] (Figure 3).  
Photolithographic patterning of silicon wafers enables production of particles with 
various geometries [69] (Figure 3), which are important for tuning their biodistribution and 
tumor accumulation [70; 71]. The S1MP have been rationally designed for overcoming 
various barriers en route to the tumor site. One of the major functions of S1MP is the 
effective interaction with the microvasculature and docking to the endothelial cells or 
fenestrations. Another task of the S1MP is to protect S2NP from degradation while in 
circulation following intravenous administration.  
 
  
Figure 3: Tailoring geometry and porosity of S1MP.
etched into silicon. A2: Electrochemically etched S1MPs with release layer. A3: S1MP array 
on wafer after removal of SiN. A4: Cross
pattern on LTO capped porous silicon film with release layer. B2: Particle array on wafer 
after RIE. B3: Discoidal S1MP array on wafer after LTO removal. B4: Released discoidal 
S1MPs. C1: Silver nanopattern etched into 
Nanowire barcode under white light. C3: SEM image of nanowire barcode. C4: 3
confocal microscopy images of nanowire barcode with green Q
segment and red Q-dot in bigger pore seg
Copyright 2014 American Chemical Society.
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 A1: Patterned SiN layer and trenches 
-section of hemispherical S1MP. B1: Photore
silicon forming porous silicon nanowires. C2: 
-dot loaded in small pore 
ment. Reproduced with permission from 
 
sist 
-channel 
[72]. 
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Further, S1MP can be surface modified with various entities including, polyethylene 
glycol (PEG) and other polymers [62], fluorescent probes [63], contrast agents, and 
biologically active tumor-microenvironment targeting moieties including antibodies [73], 
peptides [74],  thioaptamers [75] and biomimetic membranes [76]. These studies demonstrate 
that active targeting of S1MP to molecules overexpressed in the tumor microenvironment is 
very efficient. For example, conjugation of E-Selectin targeted thioaptamer (ESTA) [75] or 
arginine-glycine-aspartate (RGD) peptide [74] to the surface of S1MP enabled 20% and 10% 
of injected dose (ID) accumulation in the tumor associated vasculature. 
1.3.3 S2NP 
Subsequent to accumulating in tumor associated vasculature, S1MP can release 
second stage nanoparticles (S2NP) that are encapsulated in their pores. Liposomes[77], 
quantum dots [59], SPION [78], polymeric micelles [79], gadolinium nanotubes [80] and 
hollow gold nanospheres [81] are some examples of S2NP that have been successfully 
loaded into S1MP. Figure 4 displays an overview of the different studies where S2NP were 
loaded into S1MP.  
  
Figure 4: S2NP loading into S1MP. 
into the pores of S1MP are presented; (I) quantum dots 
gadolinium nanotubes[80], (IV) SPION 
polymeric micelles containing paclitaxel 
from the respective journal. 
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Various studies involving loading of different S2NP 
[59], (II) liposomes 
[78], (V) hollow gold nanospheres 
[79]. All figures are reproduced with permission 
 
[77], (III) 
[81] and 
  
1.3.4 Challenges in designing molecularly targeted MSV
As described in earlier sections, loading of S2NP into S1MP and conjugation of 
various targeting agents onto the surface of S1MP have been previously demonstrated 
independently. However, effective combination of the two processes poses several 
challenges. Chemical conjugation of targeting ligands on the surface of S1MP reduces the 
available surface area of pores available for the encapsulation of S2NP by as much as 75%  
[75] (Figure 5). Additionally, 
the surface of S1MP poses several technical challenges such as use of organic solvents for 
the conjugation, difficulty in the synthesis of the ligands, etc. all of which could adversely 
affect the receptor-ligand binding capability 
Figure 5: Loading of S1MP 
S1MP as measured by Inductively Coupled Plasma spectroscopy showing the decrease in the 
amount of iron loaded into the 
S1MP. Reproduced with permission from 
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chemical conjugation of peptides, antibodies or thioaptamers to 
[82] and may damage delicate S2NP 
with SPION following conjugation with ESTA. 
S1MP following conjugation of thioaptamers on the 
[84]. 
[83].   
Iron content in 
surface of 
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To overcome these challenges while combining both targeting S1MP and loading of 
S2NP, we proposed a new technique that involves, first loading of the S1MP with S2NP 
followed by decoration of the surface of S1MP with tumor targeted bacteriophage by 
electrostatic interactions. 
1.4 Targeting vascular zipcodes with bacteriophage 
1.4.1 Filamentous bacteriophage and phage display 
Bacteriophage are bacteria-specific virus which can be genetically modified to 
express a tumor-homing peptide on one of its 5 coat proteins, without compromising its 
infectivity [85]. This technique is called phage display [86]. The most commonly used phage 
for this purpose is the filamentous fd-tet bacteriophage. These are nanowire-like virus, 
measuring approximately 900nm in length and 7nm in width and having about 3900 copies 
of the major coat protein (pVIII) and 5 copies each of the minor coat proteins (pIII, pVI, pVII 
and pIX) (Figure 6). Bacteriophage expressing a tumor-targeting peptide on its coat proteins 
offers various advantages over monoclonal antibodies and conventional polymers such as; (i) 
non-toxicity, (ii) chemical and thermal stability, (iii) error-free and cost efficient mass 
production and (iv) mono-dispersity [87]. Using this technology, several tissue-specific 
surface receptor homing peptides have been identified. These peptides can be used to target 
therapeutic or imaging agents to the tumor cells. One of the main features of phage display is 
their ability to identify tissue-specific endothelial markers and the peptides that home to these 
endothelial cells. Various endothelial-specific markers have been identified in prostate cancer 
[88], in vitro HUVEC cultures [89], melanoma [90] and so on. Molecular signatures on 
vascular endothelium can also be used to target and enhance the accumulation of circulating 
nanovector at the tumor site [8]. Unlike tumor cells, these “vascular zip codes” seem to be 
  
more stable and do not give into chemotherapeutic resistance 
markers are the most accessible markers for any vascularly injected therapeutic agent, in 
comparison to markers expressed on tumor cells or stromal cells. Thus, these markers should 
be taken advantage of and used for homing ther
site.  
 
Figure 6: Bacteriophage structure and phage display
filamentous bacteriophage; (B) Schematic presentation of bacteriophage with the 5 coat 
proteins. 
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[91]. Further, endothelial cell 
apeutic agents and nanoparticles to the tumor 
. (A) TEM micrograph of 
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1.4.2 Identification of targeting ligand – CRKL binding peptide 
Recently Mintz et al. identified a new peptide sequence, 
YRCTLNSPFFWEDMTHECHA using phage display that showed marked tumor-homing in 
prostate cancer xenografts [92]. This peptide had sequence similarity with the plexin-
semaphorin integrin (PSI) domain of β1 integrin. Unexpectedly, the peptide bound to the 
extracellular fraction of an intracellular adaptor protein, CRKL.  
CRKL, a member of the Crk (CT10 Regulator of Kinase) protein family, was 
originally identified as an intracellular adaptor protein in primary leukemic neutrophils from 
patients with chronic myeloid leukemia (CML) [93]. The Crk group of proteins have been 
implicated in a wide variety of intracellular signaling pathways involving  tumor cell 
migration, invasion and survival [94]. Tissue expression of CRKL has been observed in 
various solid tumors like gastric [95], lung [96; 97],  prostate [92], hepatocellular carcinoma 
[98] and breast cancers [99; 100] as a novel prognostic marker. A recent study by Fathers et 
al. [99] established the role of Crk proteins in regulating aggressive basal breast cancers. In 
these studies, over-expression of CRKL was associated with high-grade and proliferative 
breast cancers with poor prognosis and decreased survival.  
Proteins located in various intra and extracellular compartments can have multiple 
functions based on their location [101]. When found intracellularly, CRKL has been 
implicated in integrin mediated signaling by binding to various tyrosine phosphorylated 
scaffold proteins such as C3G, paxillin and p130Cas, thus affecting adhesion and migration. 
CRKL can also translocate to the nucleus and act as a nuclear adaptor protein for Stat5 
regulating gene transcription through DNA binding [102]. While most of the studies on 
CRKL have shown that it acts as an intracellular adaptor protein in cytoplasmic or nuclear 
 20 
 
compartments, a recent work by Mintz et al. demonstrated that the unphosphorylated form of 
the protein is secreted out either by ABC transporters or when the tumor cell dies and can be 
found in the extracellular compartment of tumor [92]. The proposed mechanism of action of 
secreted CRKL involves binding to the PSI domain of β1 integrin to activate MAP kinase 
pathway causing nuclear transcription and eventual cell migration and proliferation (Figure 
7) [103]. Furthermore,  a study with mutant cells lacking CRKL suggest an important role of 
CRKL in β1 integrin mediated cell adhesion to extracellular matrix [104]. 
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Figure 7: A working model based on the switchblade integrin activation. A hypothetical 
pathway used by extracellular (secreted and/or released) CRKL to activate the integrin-
mediated MAPK cascade to promote cell proliferation and migration is shown. Reproduced 
with permission from  [103]. 
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Based on these, we hypothesized that the secreted CRKL from tumor cells would also bind to 
β1 integrins on endothelial cells of tumor associated vasculature and the CRKL targeting 
peptide can be used to target nanovectors to the endothelial cell surface bound CRKL.   
1.4.3 AuNP-bacteriophage networks 
Peptide displaying bacteriophage themselves has been used in the past for multiple 
biomedical applications such as biological sensing [105], stem cell differentiation [106] and 
therapeutic delivery [82; 85; 107]. The bacteriophage can be also be used as building blocks 
for bottom-up nanofabrication. Souza et al. demonstrated that these biocompatible and cell-
targeting bacteriophage can spontaneously organize into dense networks when combined 
with gold nanoparticles (AuNP) [108], without the requirement for genetic modifications of 
the pVIII major coat proteins or chemical conjugation between the bacteriophage and AuNP 
(Figure 8). The AuNP-bacteriophage networks have unique optical properties that can 
function as signal reporters for fluorescence and dark-field microscopy as well as near 
infrared surface enhanced Raman scattering (NIR-SERS) spectroscopy [105]. The cell-
targeting ability of bacteriophage was enhanced due to the presence of AuNP in in vitro 
melanoma cells. Au-bacteriophage networks were also detected in real-time by non-invasive 
NIR-SERS in vivo [109].   
 
  
Figure 8: Schematic illustrating the electrostatic interaction
Adapted with permission from 
 
 
1.5 Hypothesis 
The hypothesis of this work is that porous silicon S1MP can 
complexes with CRKL targeted Au
Associated Silicon Particles (BASP)
enhancing the tumor specific accumulation of the S1MP
 
23 
 of AuNP and bacteriophage. 
from [105; 108].  
spontaneously form 
-bacteriophage networks, to form Bacteriophage 
 while preserving the payload carrying potential and 
 (Figure 9). 
  
Figure 9: Schematic presentation
(BASP) that exhibit enhanced ability to marginate within blood vessels and adhere to tumor 
associated endothelium. Once positioned at the tumor site, the BASP can release its 
therapeutic or imaging payload to achi
of the carrier particle and (B) The assembly of BASP: Au
S1MP. Reproduced from [83
24 
 of (A) Bacteriophage Associated Silicon particles 
eve the desired effect prior to complete biodegradation 
-bacteriophage and non
] with permission from The Royal Society of Chemistry
-spherical 
. 
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1.6 Significance 
The aim of this study is to design multicomponent nanovectors capable of 
overcoming sequential biobarriers using specific and independent components at each stage 
and delivering substantial therapeutic agent to breast cancer tissue. The novelty of this 
project lies in the use of simple, electrostatic interactions for targeting MSV to tumor 
vasculature, while maintaining the superior payload carrying potential of the S1MP.  
 
1.7 Objectives 
The overall objective of this work was to develop a multifunctional drug delivery 
vector targeted to breast cancer tissues with good payload carrying potential. To achieve this, 
the following objectives were identified: 
• To identify a suitable vascular biomarker that can be used to target MSV in breast 
cancer.  
• To design and characterize BASP 
• To evaluate payload carrying potential of BASP 
• To evaluate in vitro and in vivo targeting ability of BASP 
• To evaluate therapeutic efficiency of BASP 
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CHAPTER 2: MATERIALS AND METHODS 
2.1 Identification and evaluation of CRKL expression in in vitro, in vivo and clinical 
samples 
2.1.1 Cell culture 
Human breast cancer cell lines MCF7, MDA-MB-231 and SUM159 were maintained 
in Dulbecco’s Modified Eagles Medium (DMEM, Life TechnologiesTM, NY, USA) 
supplemented with 10% fetal bovine serum (FBS, Life TechnologiesTM, NY, USA) and 1% 
penicillin (100units/mL) and streptomycin (100µg/mL). Human breast epithelial cell line 
(MCF10A) was maintained in DMEM/F12 media (Life TechnologiesTM, NY, USA) 
supplemented with 5% horse serum (Life TechnologiesTM, NY, USA), 20ng/mL epidermal 
growth factor (EGF, PeproTech, NJ, USA), 500µg/mL hydrocortisone (Sigma-Aldrich Co., 
MO, USA), 100ng/mL cholera toxin (Sigma-Aldrich Co., MO, USA), 10µg/mL insulin 
(Sigma-Aldrich Co., MO, USA) and 1% penicillin and streptomycin. 
Human umblical vein endothelial cells (HUVEC, Lonza Inc., USA) were maintained 
in Endothelial Basal Medium -2 (EBM-2) supplemented with EGM-2 Bulletkit (Lonza Inc. 
USA). Human microvascular endothelial cells (HMVEC, ATCC) were maintained in EBM-2 
supplemented with EGM-MV bulletkit (Lonza).  
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2.1.2 Tumor models 
Orthotopic mouse models of breast carcinoma were developed by inoculating 5x104 
EF43.fgf4 cells into the mammary fat pad of 5 – 7 week old Balb/C mice as previously 
described [110]. The tumors were allowed to grow for 5 days and the mice were sacrificed to 
harvest the tumor for immunohistochemical and immunofluorescence staining. Patient 
derived tumor xenograft (2665A) and human cell line (MDA-MB-231) orthotopic xenograft 
sections were kindly provided by Dr. Bhuvanesh Dave. Human cell line (SUM159) xenograft 
sections and 4T1 cell line tumor sections were also collected for CRKL staining analysis. All 
animal procedures were approved by the Institutional Animal Care and Use Committee 
(IACUC) of Houston Methodist Research Institute.  
2.1.3 Patient samples 
Progressive breast cancer tissue microarrays were purchased from the Cancer 
Diagnosis Program (National Cancer Institute). A total of 94, formalin fixed and paraffin 
embedded, tumor tissue blocks corresponding to samples from different stages of disease 
progression classified using TNM (American Joint Committee on Cancer, VI edition) were 
studied. Twenty three specimens of normal breast tissue surgically removed with the 
cancerous tissue were used as controls. Patient related data including age, disease stage, 
tumor size, nodal involvement, metastatic status, estrogen and progesterone receptor status 
for the included specimens were provided. This study was approved by the Institutional 
Review Board (IRB) at the National Cancer Institute. Informed consent was not required for 
these samples.10x and 40x images were captured using a Nikon microscope and the intensity 
of staining was measured using NIS elements software. 
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2.1.4 Evaluation of surface bound CRKL by flow cytometry 
Presence of CRKL on the surface of various cells was analyzed using CRKL antibody 
by flow cytometry analysis. Cells grown to 80% confluency in 6 well plates were harvested 
and incubated with CRKL antibody (Santa Cruz Biotechnology, TX, USA) for 45min 
followed by incubation with APC-labeled secondary antibody (Santa Cruz Biotechnology, 
TX, USA) for 1h. They were then washed and re-suspended in PBS for flow cytometric 
analysis. Cells incubated with the secondary antibody alone were used as controls. Cells were 
measured on a BD FACS Fortessa analyzer (BD Biosciences, CA, USA) using 561nm 
excitation laser. Twenty thousand cells were counted for each sample. Analyses of flow 
cytometric data focused only on live cells using electronic gate to identify the APC positive 
events using BD FACSDivaTM software. All experiments were performed in triplicates. 
2.1.5 Assessment of cellular localization of CRKL using immunofluorescence 
The pattern of CRKL staining in cells was analyzed by immunofluorescence. Cells 
were seeded in 8 chamber slides (BD Bioscences, CA, USA) with 80% confluency and 
allowed to attach overnight. After fixation with 4% paraformaldehyde (PFA, Thermo 
Scientific, IL, USA), they were ramdomly divided into two groups. In one group the cells 
were permeabilized with 0.2% TritonTM X-100 (Sigma-Aldrich Co., MO, USA) for 5 min 
and washed extensively. In the second group, the cells were not permeabilized, to specifically 
analyze the membranal fraction of CRKL. Both categories were incubated with CRKL 
antibody at 1:500 dilution for 1h at room temperature (RT), washed and incubated with 
Dylight 594-conjugated goat anti-rabbit secondary antibody (Thermo Scientific, IL, USA) for 
45min. After the cells were washed, they were fixed again with 4% PFA, mounted with 
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DAPI containing Prolong gold (Life TechnologiesTM, NY, USA) and visualized under a 
Nikon fluorescence microscope (Nikon Instruments Inc., NY, USA). 
2.1.6 Evaluation of CRKL expression in tumor using immunohistochemistry and 
immunofluorescence 
Immunohistochemical staining was performed on paraffin-embedded tumor sections 
to study CRKL expression pattern. After two washes the slides were blocked for 10min in 
peroxidase followed by 2.5% horse serum (Life TechnologiesTM, NY, USA) for 10min; 
reacted with anti-CRKL antibody (1:100) for 30min; washed  three times; incubated for 
15min with horse anti-rabbit IgG; reacted for 4min with diaminobenzidine; rinsed; counter-
stained with hematoxylin; mounted; and imaged. The intensity of staining was determined by 
image analysis using Nikon’s imaging software – NIS elements. 
Cryosections were fixed in cold acetone for 5min, air dried and subsequently blocked 
with 5% goat and horse serum in PBS for 30min at RT. Sections were then incubated with 
primary antibodies (CRKL antibody and anti-CD31 antibody) for 1h at RT or overnight at 
4°C, washed and incubated for 1h with APC conjugated anti-rabbit antibody and FITC 
conjugated anti-mouse IgG. Tissue sections were washed, mounted and imaged using Nikon 
A1 confocal microscope or Nikon fluorescence microscope. 
2.2 Nanovector design and fabrication 
2.2.1 S1MP fabrication 
“S1MP were fabricated by integration of photolithography and electrochemical 
etching of p-type silicon wafers in the Microelectronics Research Centre at The University of 
Texas at Austin, as previously described [59; 71]. Briefly, the dimensions of S1MP were 
defined by photolithography while the porous structure was formed by electrochemical 
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etching of silicon in a mixture of hydrofluoric acid (HF) and ethanol. Particles with different 
geometries and porosities were evaluated in this study including quasi-hemispherical and 
discoidal particles with mean pore sizes of 20–30nm or 50–60nm. Photolithography followed 
by electrochemical etching was used to make quasi-hemispherical S1MP [69]. For discoidal 
S1MP, electrochemical etching was performed before photolithography [9]. The current 
density was varied to obtain different pore sizes. Unmodified S1MP were retained on the 
substrate for washing steps, and then released by sonication in isopropyl alcohol (IPA). The 
particles were dried, and oxidized in a piranha solution (3:1 solution of sulfuric acid and 30% 
hydrogen peroxide) at 100-110ºC for 2h to yield S1MP with negative surface charge 
[S1MP(-)]. To produce S1MP with positive zeta potential [S1MP(+)], S1MP(-) were reacted 
with 2% 3-aminopropyltriethoxysilane (APTES, Sigma-Aldrich Co. LLC, USA)  for 2h at 
35°C. The modified particles were re-suspended and stored in IPA. Immediately before use, 
the particles were washed thrice and re-suspended in distilled water. The concentration 
(counts/mL) of S1MP was obtained using a MultisizerTM 4 Coulter Counter (Beckman 
Coulter, USA). The zeta potential was measured with ZetaPALS (Brookhaven Instruments 
Corporation, USA).” [83] 
2.2.2 AuNP synthesis 
“Gold nanoparticles (AuNP) were prepared using the common Turkevich method 
[111] with a ratio of 1:0.8 of Gold(III) chloride and trisodium citrate (Sigma-Aldrich Co. 
LLC, USA) to yield ~45nm particles. The resulting AuNP colloid solution was concentrated 
by sequential centrifugation steps at 2600xg in Sorval Legend X1R Centrifuge (USA) for 10, 
15 and 20min at 4°C to achieve an absorbance of approximately 5A.U. at 530nm. The 
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hydrodynamic radius and the zeta potential measurements of AuNP were performed using 
ZetaPALS.” [83] 
2.2.3 Bacteriophage isolation 
“Bacteriophage particles were obtained as previously described [112]. Briefly, 
filamentous bacteriophage, both native (fd-tet) and YRCTLNSPFFWEDMTHECHA 
peptide-displaying (CRKL targeted), were grown by infection of K91 Escherichia coli 
(E.coli) bacteria overnight at 37°C and were subsequently isolated by PEG precipitation [82; 
113]. The final pellet was resuspended in phosphate-buffered saline (PBS). Endotoxin free 
bacteriophage were obtained by phase separation using TritonX-114[114]. Bacteriophage 
titers or transducing units (TU) were determined by infecting E.coli and screening for 
tetracycline resistant colonies. Fluorescently labeled bacteriophage was used for 
identification by confocal microscopy when needed. The bacteriophage particles were 
conjugated with a 1000 fold excess of Dylight 594 (Thermo Fisher Scientific Inc., USA) for 
1.5h and precipitated using PEG.” [83] 
2.3 Assembly of Bacteriophage Associated Silicon Particles (BASP) 
“AuNP-bacteriophage networks were obtained based on the previously published 
method [105] with a bacteriophage input of 2.5x107 TU/µL. Two-fold serial dilutions of 
bacteriophage were done in distilled water and equal volumes of AuNP were added to each 
dilution and left undisturbed overnight at RT. The formation of AuNP-bacteriophage 
networks was noted by a change in colour of the solution from red to purple [105]. AuNP-
bacteriophage networks were concentrated and incubated with S1MP for 1h with intermittent 
vortexing to form BASP.” [83] 
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2.4 Characterization of BASP 
2.4.1 Visualization of BASP formation  
The morphology of the BASP was examined using various microscopic techniques. 
2.4.1.1 Confocal microscopy 
“For identification during confocal microscopy studies, S1MP(+) were loaded with 
fluorescein isothiocyanate conjugated bovine serum albumin (BSA-FITC, Sigma-Aldrich Co. 
LLC, USA). For this purpose 107 S1MP(+) were desiccated to remove any residual IPA. To 
the dry S1MP(+) 200µL of 5mg/mL aqueous solution of BSA-FITC was added and the 
system was incubated for 2h at 4ºC under rotation. The loaded particles were washed thrice 
in distilled water and incubated with Dylight 594 conjugated bacteriophage to form BASP 
and were visualized under a Leica DM6000 upright confocal microscope (Leica 
Microsystems, Germany) equipped with a 63X oil immersion objective.” [83] 
2.4.1.2 Transmission Electron Microscopy 
“For transmission electron microscopy (TEM), samples were placed on 100 mesh 
coated copper grids treated with poly-l-lysine for 1h. Excess samples were blotted with filter 
paper and the BASP were stained with filtered aqueous 1% ammonium molybdate and 0.02% 
BSA, pH 7.0 for 1min. The samples were blotted, allowed to dry and imaged using the AMT 
Imaging System (Advanced Microscopy Techniques Corp., Danvers, MA) JEM 1010 TEM 
(JEOL, USA, Inc., Peabody, MA) at 80kV fitted with an AMT Advantage digital CCD 
camera system.” [83] 
2.4.1.3 Scanning Electron Microscopy 
“BASP solutions were dried on cleaned SEM stubs overnight in a desiccator and 
sputter-coated with a 5nm layer of gold, using a Plasma Sciences CrC-150 Sputtering System 
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(Torr International, Inc.). Scanning electron microscopy (SEM) images were acquired under 
high vacuum, at 20kV, spot size 3 – 5, using an FEI Quanta 400 FEG ESEM (FEITM, USA) 
equipped with an ETD (SE) detector.” [83]  
2.4.2 Effect of porosity and zeta potential of S1MP on BASP formation  
“To study the effect of surface charge and porosity of S1MP in the formation of 
BASP, we incubated the systems with various geometries, porosities and surface charges of 
S1MP. The geometries of S1MP varied from quasi-hemispherical to discoidal to cylindrical 
with size ranges between 0.4µm to 3µm. The pore sizes of S1MP used were either 20-30nm 
(huge pore, HP) or 40-60nm (giant pore, GP). The surface charge of the S1MP used was 
modified by oxidation to yield a negative zeta potential or by silanization to yield a positive 
charge as described earlier.” [83] 
2.4.3 Evaluation of contact angle 
“The hydrophilicity of the systems was determined by measuring the contact angles 
made by the sample solution resting on a flat horizontal solid surface using captive bubble 
contact angle goniometry.” [83] 
2.4.4 Spectral characteristics of BASP 
“Light spectroscopy was used to study the absorption characteristics of BASP during 
their formation. Shifts in the absorbance spectra of AuNP towards the NIR wavelengths were 
evaluated using SpectraMax M2 spectrophotometer (Molecular Devices, USA) or Biotek 
Synergy H4 hybrid multimode microplate reader (BioTek® Instruments, Inc., USA).  
For SERS, BASP were excited by a fiber-optic probe delivering 785nm laser light for 
10s.  The resulting Raman scattering data (average of 3 results) were gathered on a 
PerkinElmer Raman Station 400F (PerkinElmer Inc., USA) after background subtraction 
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with water. The spectra were analyzed with Spectrum software (PerkinElmer Inc., USA).” 
[83] 
2.4.5 Thermal effects of BASP 
“The enhanced absorbance in the NIR region prompted the use of NIR laser to test the 
heating potential of BASP. 200µL of the sample solution was exposed to Delta 810nm diode 
laser (AngioDynamics UK Ltd.) with an output of 10J/cm2 for 250msec at an interval of 
100msec for a total of 10min using a 2mm fixed focus spot hand-piece. The resulting change 
in temperature was measured using an OxyLiteTM probe (Oxford optotronix Ltd., USA).” 
[83] 
2.5 In vitro degradation of BASP 
“BASP or S1MP (5x107, 1.6µm quasi-hemispherical) were suspended in 1mL of 
100% FBS and incubated at 37°C with constant mixing in a rotary shaker for predetermined 
times. Aliquots (100µL) were taken at specified time intervals namely 0, 0.5, 1, 4, 8, 24 and 
48h. For quantitative analysis of elemental silicon in the degradation medium, 90µL of the 
aliquots were filtered through a microcentrifuge filter to separate the non-degraded S1MP 
from the degradation products, diluted with water and analyzed using Varian 720-ES 
Inductively Coupled Plasma – Optical Emission Spectrometer (ICP-OES, Varian Inc., USA) 
set at 1kW, with plasma flow set to 15L/min, auxiliary flow of 1.5L/min and a nebulizer flow 
of 0.75L/min. Silicon contents in the degradation medium was detected at 250.69nm, 
251.43nm, 251.61nm and 288.158nm using 1ppm of Yttrium as an internal control.  The 
remaining 10µL were washed thrice with deionized water to remove salts and proteins and 
processed for SEM analysis as described above.” [83] 
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2.6 Loading of S2NP 
“S1MP (1.5x108, 1x0.4µm discoidal, 20-30nm pore size) and E-Selectin thioaptamer 
conjugated S1MP (ESTA-S1MP) were dried in a desiccator. For ESTA-S1MP, the S1MP 
were conjugated with a 107 fold excess of thioaptamers using PolyLink Protein Coupling kit 
for 1h as described earlier [75]. Amine modified SPION (15nm) suspended in PEG was 
centrifuged at 2000rpm for 5min at RT to remove aggregated particles. The supernatant was 
used as the stock for loading experiments. SPION solution (25µL) was added to S1MP and 
incubated for 30min with intermittent sonication. The SPION loaded S1MP were washed 
twice with water and then incubated with 15µL AuNP-bacteriophage networks for 1h to 
allow the assembly of BASP. The BASP were washed an additional time to remove any 
unbound SPION. NMR relaxation profiles of the SPION loaded particles were measured 
using a Bruker Minispec mq-60 bench-top relaxometer (Bruker Optics Inc., USA) operating 
at 60MHz and 37°C. The solutions were then digested for evaluation of elemental iron by 
heating them with nitric acid at 120°C thrice until the acid evaporated. The sediments were 
then resuspended in water. The iron content was detected at 238.204nm and 259.940nm 
using ICP-OES as previously described. 
S1MP (1.5x108, 1x0.4µm discoidal, 20-30nm pore size) were loaded with 20µL of 
2µM carboxylated quantum dots (QD) in a process similar to the SPION loading. Following 
BASP formation, the particles were visualized under fluorescence microscope to see if the 
QD are confined to the S1MP in the BASP or are released and entrapped in the AuNP-
bacteriophage networks during the BASP formation. The samples were also digested using 
nitric acid and analysed for Cadmium content using ICP-OES.” [83] 
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S1MP were loaded with Abraxane also using the wet incipient method. Abraxane was 
reconstituted at 1.5mg/20µL of distilled water and added to 1x109 S1MP. After 1h of rotation 
at RT, the S1MP were either reconstituted in a total of 100µL water or AuNP-bacteriophage 
networks to form BASP. 
2.7 In vitro studies 
2.7.1 Evaluation of cellular association of BASP  
To study the in vitro behavior of BASP, endothelial cell lines (HUVEC and HMVEC) 
and breast cancer cell line (MCF7) with the maximum amount of surface CRKL were 
incubated with BASP and observed. HUVEC and HMVEC were seeded at 200,000 cells/well 
in a 12 well plate (BD Falcon) and allowed to grow overnight at 37ºC. Cells were blocked 
with 30% FBS for 1h at 37ºC and were incubated with BSA-FITC (Sigma Aldrich) loaded 
S1MP,  non-targeted BSA-FITC loaded fd-tet BASP or CRKL targeted BSA-FITC loaded 
BASP for upto 1h. The cells were subsequently washed, fixed with 4% PFA and resuspended 
in PBS for analysis by flow cytometry. 
MCF7 cells seeded at 70% confluency on 8 chamber microscope slides (BD Falcon) 
and allowed to grow overnight at 37°C. Cells were blocked with 30% FBS for 1h at 37°C 
and were incubated with BSA-FITC (Sigma Aldrich) loaded S1MP, non-targeted BSA-FITC 
loaded fd-tet BASP or CRKL targeted BSA-FITC loaded BASP for 6h. The cells were 
subsequently washed and fixed with 4% PFA, permeabilized with 0.2% Triton X-100 and 
blocked with 1% BSA (SigmaAldrich) for 1h. The phage were stained with rabbit anti-phage 
primary antibody (Sigma Aldrich) followed by Dylight-594 tagged goat anti-rabbit secondary 
antibody. The cells were stained with nuclear stain, Draq 5 (Biostatus Ltd.), fixed and imaged 
using a Leica Confocal microscope. 
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MCF7 cells were plated in 24 well plates containing 5 x 5mm Silicon Chip Specimen 
Supports (Ted Pella, Inc., Redding, CA) at 70% confluency. Cells were incubated with 
S1MP, fd-tet BASP or CRKL targeted BASP (5 particles/cell) at 37ºC for 6h. Samples were 
washed with PBS and fixed in 2.5% glutaraldehyde (Sigma-Aldrich) for 30min and 
processed for SEM analysis as described previously [115]. Briefly, the cells were dehydrated 
in a step-wise manner in increasing concentrations of ethanol (30%, 50%, 70%, 90%, 95% 
and 100%) for 10min each. The cells were then incubated in 50% t-Butanol for 10min 
followed by incubation in 100% t-Butanol for 5min and overnight incubation in a dessicator. 
Specimens were then mounted onto SEM stubs (Ted Pella, Inc.) with conductive adhesive 
tape, sputter coated with 5nm layer of gold and imaged under high vacuum, at 20-30 kV, spot 
size 3.0-5.0, using a FEI Quanta 400 FEG ESEM equipped with an ETD (SE) detector. 
MCF7 cells were grown to 70% confluency in a 24 well plate and incubated with 
S1MP, fd-tet BASP or CRKL targeted BASP (5 particles/cell) at 37ºC for 6h.  Cells were 
washed and fixed in a solution of 2% PFA and 3% glutaraldehyde in PBS, pH 7.4 for 1h at 
RT. Samples were processed for TEM as described previously [115]. Briefly, the samples 
were washed with 0.1% cacodylate buffered tannic acid, fixed with 1% osmium tetroxide for 
30min and stained with 1% uranyl acetate. The cells were then dehydrated in increasing 
concentrations of ethanol as described before, infiltrated, embedded in Poly-bed 812 medium 
and polymerized for 2 days at 60ºC. Ultra-thin sections were cut and stained with uranyl 
acetate and lead citrate. The samples were imaged in a JEM 1010 TEM microscope as 
described above. 
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2.7.2 Evaluation of interaction with endothelial cells under shear stress 
HUVEC or HMVEC cells were seeded at 1.5x107 cells/mL density on fibronectin 
coated Bioflux microfluidic 48 well plates (0-20 dynes/cm2) and allowed to grow overnight. 
To activate endothelial cells, cells were seeded and allowed to attach for 1h. They were then 
incubated with conditioned media from EF43.fgf4 cells overnight. Cells were then treated at 
37ºC with one of the following: Alexafluor 555 conjugated S1MP, fd-tet BASP or CRKL 
targeted BASP under constant linear flow at either 10s-1 or 100s-1 shear rates at a 
concentration of 107 particles/mL. Briefly, APTES modified particles (1x109) were incubated 
with 0.5mg/mL solution of Alexa fluor 555 (Life TechnologiesTM, NY, USA) for 1h at RT. 
The particles were then washed to remove unbound dye and again APTES modified before 
BASP formation. The flow of the particles over the cells was recorded by taking timelapse 
images in the TRITC channel at 12 frames per second for 1h using a 20X objective on an 
inverted Nikon microscope. The particles were removed and replaced with fresh media and 
the cells were monitored for an additional 16h with images being taken every 1h. The 
velocity of particles rolling on the cell surface and the number of particles attached were 
analyzed using NIS elements software equipped with 2D tracking component.  
2.8 In vivo studies 
2.8.1 Evaluation of targeting efficiency of CRKL targeted BASP 
Breast cancer allografts were grown in immunocompetent Balb/c mice by injecting 
5x104 EF43.fgf4 cells orthotopically in the mammary fat pad. After 10 -14 days, the mice 
were randomly divided into 4 groups and administered intravenously with one of the 
following: PBS, S1MP, fd-tet BASP or CRKL targeted BASP formed with 5x108 S1MP 
(1.6µm quasi-hemispherical). The bacteriophage used in these experiments were either 
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labeled with Dylight 594 or unlabeled. Four hours following the administration of the 
systems, the animals were sacrificed and the liver and tumor were collected for histological 
analysis (conventional and hyperspectral microscopy). Paraffin embedded tissue sections 
were stained for bacteriophage by incubating with anti-bacteriophage antibody (Sigma 
Aldrich Co. LLC., USA) at 1:750 dilution for 30min. Frozen tissue sections from mice 
injected with Dylight 594 labeled bacteriophage containing BASP were counterstained for 
nucleus with Draq5 (Biostatus Limited, UK). Non-stained paraffin embedded tissue sections 
were fixed with 4% PFA, mounted with Prolong gold mounting media (Invitrogen, USA) and 
imaged using a darkfield condenser from CytoViva attached to an Olympus BX41 
microscope and DAGE camera/software (CytoViva, Auburn, AL 36830) hyper-spectral 
imaging system that can identify material at resolutions of less than 100nm based on the 
material’s unique spectral signatures. 
2.8.2 Evaluation of therapeutic efficacy of CRKL targeted BASP 
Abraxane was purchased from MD Anderson Cancer Center (Houston, TX) 
pharmacy and diluted in water before use. To assess the therapeutic activity of S1MP or 
CRKL targeted BASP loaded with Abraxane, Balb/C mice bearing orthotopic EF43.fgf4 
tumors on either side of their body were randomly divided into 4 groups (5 mice/group) and 
treated with: (i) PBS, (ii) Abraxane (Abx) (75mg/kg), (iii) S1MP-Abx (75mg/kg) or (iv) 
CRKL targeted BASP-Abx (75mg/kg). The mice were treated every third day and the tumor 
size was monitored every other day using calipers until the 11th day 
2.8.3 Intravital microscopy for studying particle flow characteristics 
Orthotopic breast tumor bearing mice were randomly selected for intravital 
microscopy studies on days 5 and 10. The anaesthetized mice were surgically opened to 
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expose the tumor mass, positioned on a heated stage and injected with 5x108/100µL particles 
of either Alexa Fluor 555 labeled S1MP or fd-tet BASP or CRKL targeted BASP. 
Immediately following injection, three channel images were acquired as a time lapse video at 
30 frames per second using a 40x0.6 NA objective. Animals were imaged for 1h and then 
sacrificed as described above, to collect organs for histological analysis. 
2.9 Evaluation of CRKL as a soluble biomarker 
2.9.1 Collection of conditioned media (CM) for evaluation of secreted CRKL 
Conditioned media (CM) were collected from SUM159 and MCF10A cell lines. The 
cells were seeded at 50% confluency overnight, washed with PBS and incubated with serum 
free media for 24h. The media was then collected, centrifuged at 5000rpm for 10min and the 
supernatant was stored at -80°C until analysis by ELISA. 
2.9.2 Evaluation of secreted serum fraction of CRKL in in vivo models 
Blood from nude mice grafted with patient derived breast tumors (2665A) were 
collected for enzyme linked immunosorbant assay (ELISA). All animal procedures were 
approved by the Institutional Animal Care and Use Committee (IACUC) of Houston 
Methodist Research Institute. 
2.9.3 Collection of patient serum samples 
Twenty nine breast cancer patients’ sera and 9 healthy donor serum samples were 
purchased from Promeddx, LLC (Massachusetts) and tested for soluble CRKL fraction by 
ELISA.  As in the tissue microarrays, the serum samples were from patients with different 
stages of disease progression classified using TNM staging. Twenty five out of the twenty 
nine patients were undergoing treatment. This study was approved by the IRB at Promeddx 
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LLC. Informed consent was obtained or implied by return of questionnaires at the 
physician’s site. 
2.9.4 Evaluation of soluble fraction of CRKL by Enzyme Linked Immunosorbant 
Assay 
The levels of secreted CRKL in cell culture supernatants, serum samples from mice 
bearing 2665A breast tumors and breast cancer patients sera were analyzed using 
commercially available ELISA kits (Cloud-Clone Corp., TX, USA) according to 
manufacturer’s instructions. The CRKL concentrations are expressed as pg/mL of blood 
plasma. Detection limit was 53pg/mL. 
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CHAPTER 3: RESULTS 
3.1
 
CRKL as a cell surface biomarker 
3.1.1
 
Localization on cell surface  
A previous study has shown that CRKL, originally an intracellular protein is secreted 
by tumor cells into the tumor microenvironment [92]. We speculated that “the secreted 
CRKL from tumor cell lines would bind to the surface of cells through interaction with β1 
integrin. To evaluate the membrane bound fraction of secreted CRKL, non-permeabilized 
breast cancer cells were analyzed by flow cytometry. The percentage of cells with surface-
bound CRKL varied among different cell lines. Cancer cell lines (MCF7, MDA-MB-231 and 
SUM 159) showed 3 – 5 fold higher percentage of staining than mammary epithelial cell line 
(MCF10A). For instance 93.7% of MCF7 cells have surface bound CRKL when compared to 
55.6% on SUM159 cells and only 17% on MCF10A cells (Figure 10A).” Murine breast 
cancer cell lines EF43.fgf4 and 4T1 also showed very high staining for CRKL – upto 80%.  
We also looked at the surface localization of CRKL in endothelial cells. The surface 
fraction of CRKL in endothelial cells can serve as an indicator of the fraction released from 
cancer cells. Moreover, since β1 integrin is overexpressed on angiogenic vasculature, we 
hypothesized that higher fractions of CRKL will be bound to the surface of tumor associated 
endothelial cells.  The levels of surface bound CRKL were 82.2±4.7%, 25.9±12.7% and 
13.7±1.1% for SVEC, HUVEC and HMVEC respectively (Figure 10B). Addition of cancer 
cell conditioned media (EF43.fgf4 – CM) to HMVEC increased the surface localization of 
CRKL on HMVEC by about 2 fold (Figure 10C).  
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Immunofluorescence staining of the various cell lines confirmed the presence of 
CRKL on the cell surface. The lack of co-localization of nuclear (DAPI) and CRKL staining 
in non-permeabilized cells confirmed that the observed staining is the surface-bound fraction 
of CRKL. On the other hand, permeabilization of the cells led to the staining of the 
cytoplasm and the nuclear region showing that, as expected, a large fraction of the protein is 
present in intracellular compartments (Figure 10D). 
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Figure 10: Surface localization of CRKL in breast cancer cells in vitro. Flow cytometry 
on non-permeabilized cells showing surface fraction of CRKL in (A) breast cancer and 
epithelial cell lines; (B) endothelial cell lines and (C) HMVEC incubated with cancer 
conditioned media. (D) Immunofluorescence images of human breast cancer and endothelial 
cells showing the  difference in the staining pattern of CRKL (red) in permeabilized (bottom 
row) and non-permeabilized (top row) cells. The cells are counterstained with wheat germ 
agglutinin 488 for the cell membrane (green) and DAPI for the nucleus (blue). (Scale bar = 
20µm) 
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3.1.2
 
Expression in in vivo and clinical tumor biopsies 
Next, we “evaluated the patterns of CRKL expression in in vivo breast tumor models 
originated from a human clinical specimen (2665A) and human breast tumor cell lines MDA-
MB-231 and SUM159. MDA-MB-231 xenografts exhibited cytoplasmic/membranal staining 
for CRKL, while SUM159 and patient derived xenograft 2665A showed stronger nuclear 
staining with mild cytoplasmic and extracellular staining.” Murine breast tumor models from 
EF43.fgf4 and 4T1 exhibited mainly extracellular CRKL staining (Figure 11A).  
To evaluate the CRKL expression in human breast cancer specimens, we 
immunostained paraffin embedded cancer progression tissue microarrays with a total of 94 
tumor cores (Figure 11B). It was noted that normal breast tissue stained positive for CRKL 
only in the ductal epithelium, therefore, during the pathological examination of the tumor 
tissue, the regions of ductal epithelium were excluded. More than 90% of the patients were 
Caucasians. Twenty seven patients were estrogen receptor (ER) negative and 46 were 
progesterone receptor (PR) negative. The average tumor size of the entire set of patients was 
2.6 cm (range from 1 to 6.5 cm).  
Similar to in vivo studies, the staining pattern in tumor tissue varied from nuclear to 
cytoplasmic to microenvironmental. Overall, about 85% of the breast cancer clinical samples 
stained positive for CRKL. The average intensity of CRKL (A.U./pixel), as measured by 
image analysis, was about 12 fold higher in breast tumor biopsies than in the uninvolved 
breast tissue (46.8±22.1 vs 3.9±1.9 A.U./pixel, respectively, Figure 11C). Table 3 
summarizes the correlation of CRKL staining and the clinicopathological factors. 
  
Figure 11: CRKL expression in 
Immunohistochemistry for CRKL in (A) primary breast cancer xenografts (Scale bar = 
50µm); (B) Immunohistochemistry of 
strong and (ii) weak staining of invasive ductal carcinoma tissues, (iii) normal breast tissue 
showing positive staining mainly in the ductal ep
Quantitation of intensity of staining through image analysis in tumor cores (early and 
advanced disease) and normal breast tissues.
46 
in vivo samples and clinical tumor biopsies
human breast cancer tissue microarray showing (i) 
ithelium. (Scale bar = 100µm) (C
 
. (A) 
) 
  
To confirm our findings regarding surface fraction of CRKL on endothelial cells from 
in vitro studies, we tested co
cancer allografts and CD34 for human tissue 
sections. A stronger CRKL staining on tumor associated endothelial cells as compared to the 
overall tumor mass staining was observed
the tissue microarray (Figure 1
 
Figure 12: Co-localization of CRKL and tumor associated vasculature. 
Immunofluorescence staining of CRKL and (A) CD31 in EF43.
(B,C,D) CD34 in human breast cancer tissue microarray biopsies, showing co
CRKL and vascular endothelial cells in the tumor.
47 
-localization of CRKL and endothelial marker (CD31 for breast 
microarray) staining in histol
 in both the animal model (Figure 12A) as well as 
2B,C,D). 
fgf4 breast allograft model; 
 
ogical tumor 
 
-localization of 
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 Staining intensity of CRKL in breast cancer tissue 
microarray 
 Negative Positive  
Parameters Number % Number % P 
Age      
<60 years 10 19.6 41 80.4 0.86 
>60 years 9 20.9 34 79.1  
T stage      
T1 7 16.2 36 83.8 0.001 
T2 8 20 32 80  
T3 1 33.3 2 66.7  
T4 3 37.5 5 62.5  
Nodal involvement      
Negative 3 9 30 91 0.007 
Positive 11 24.4 34 75.6  
Metastatic involvement      
Negative 10 16.4 51 83.6 0.08 
Positive 9 27.3 24 72.7  
Tumor size      
< 2 cm 7 15.9 37 84.1 0.22 
> 2 cm 12 24 38 76  
Estrogen receptor      
Negative 4 14.8 23 85.2 0.27 
Positive 15 22.4 52 77.6  
Progesteron receptor      
Negative 7 15.2 39 84.8 0.11 
Positive 12 25 36 75  
Table 3: Relationship between CRKL expression and clinicalpathological parameters 
Based on the above observations, we decided to see if the extracellular fraction of 
CRKL could serve as a target for targeted drug delivery of nanovectors. 
3.2
 
Physical characterization of BASP 
3.2.1
 
Assembly of BASP 
“BASP are comprised of three components: S1MP, AuNP and bacteriophage. The 
addition of AuNP to bacteriophage causes instantaneous agglomeration of AuNP noted by 
the color change from red to purple [105] and the condensation of the system into fibrous 
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structures as seen in Figure 13A, similar to what was previously reported by Souza et 
al.[105] Addition of these condensed AuNP-bacteriophage networks to S1MP resulted in 
spontaneous association between the components forming BASP. To verify the formation of 
BASP we used confocal microscopy and TEM. Fluorescently labeled bacteriophage used in 
the assembly of BASP clearly showed co-localization of the bacteriophage (red) and the 
BSA-FITC loaded S1MP (green) (Figure 13B). Further, TEM micrographs showed the close 
association of fibrous bacteriophage (white lines) and AuNP (black dots) with S1MP (a large 
porous structure) (Figure 13C).” [83] 
 
  
Figure 13: Visualization of the BASP formation
formation corresponding to the association of AuNP
form BASP at serial dilutions of the bacteriophage starting from the concentration of 
3.87x105 TU/µL ; (B) Confocal microscopic imag
S1MP(+) (Green) and Dylight594 labeled phage (Red) showing the specific co
of the two; (C) TEM image of BASP showing the S1MP surrounded by AuNP(arrow heads) 
and bacteriophage(arrows). Reproduced 
of Chemistry. 
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. (A) Macroscopic view on network/gel 
-bacteriophage networks with S1MP to 
e of BASP with BSA
from [83] with permission from The Royal Society 
-FITC loaded 
-localization 
  
“Optimization processes in t
concentrations of the components in a systematic manner. 
of AuNP (OD 1 to 7) did
concentrations of silica beads (>10
found that formation of BASP was most efficient when assembled in a two
involving: (1) the formation of dense AuNP
coating of S1MP by these networks (Figure 14
51 
he assembly of BASP involved incubation of various 
It was seen that the concentration 
 not affect the formation of BASP, while excessively high 
6/µL) prevented their formation (Figure 14
-bacteriophage networks; followed by the
B).” [83]  
A). Also, it was 
-step process 
 (2) 
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Figure 14: Effect of concentration and order of incubation on the formation of BASP 
(A) Photographs showing the assembly of BASP with different concentrations of the 
components. The red color is due to the presence of AuNP. Note the condensation and the 
color change in the solution (highlighted in the blue box) at bacteriophage concentrations of 
3.5x106, 1.75x106 and 8x105 TU/µL in A as opposed to the absence of such changes in B. (B) 
SEM micrographs of BASP with silica beads. Left: BASP formation when bacteriophage 
was added to a mixture of silica beads and AuNP. Right: BASP formation when AuNP-
bacteriophage networks were added to silica beads.  Note the significant increase in the 
number of AuNP (white dots) and the presence of fibrous coating on the silica beads 
(bacteriophage) in B. Adapted and reproduced from [83] with permission from The Royal 
Society of Chemistry. 
 
3.2.2
 
Effect of porosity and zeta potential of S1MP on BASP formation 
“We compared non-porous spherical silica beads to quasi-hemispherical and discoidal 
mesoporous silicon particles with different pore sizes in their ability to form BASP. Although 
the shape of S1MP used did not have much effect on the self-assembly of BASP, the 
association of AuNP to porous particles was evidently better than their association to non-
porous silica beads (Figure 15).” [83] 
  
Figure 15: BASP design- effec
BASP formed in the presence of S1MP(
images show the association of S1MP with AuNP. The systems are as follows: (a) 1.6µm in 
diameter quasi-hemispherical HP (b) 1µm in diameter and 0.4µm in
3.2µm in diameter quasi-hemispherical HP (d) 1µm in diameter and 0.4µm in height 
discoidal HP (e) 0.6µm in diameter and 0.4µm in height discoidal HP (f) 1µm in diameter 
spherical solid silica beads. GP 
300µm. Reproduced from [83
53 
t of S1MP geometry and porosity. (A) SEM images of 
-) with different geometries and porosities. The 
 height discoidal GP (c) 
– pore size 40 – 60nm, HP – pore size 20 – 30nm, Scale bar 
] with permission from The Royal Society of Chemistry.
- 
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“The surface potential of drug delivery vehicles is another important feature to be 
considered in their design. The effect of zeta potential of S1MP on the formation of BASP 
was evaluated by comparing BASP containing 1.6µm quasi-hemispherical S1MP(+) and 
S1MP(-). The initial and final zeta potential values of the systems are presented in Figure 16 
For S1MP(+) and S1MP(-), the initial zeta potential values were 8.9 ± 1.9mV and -25.7 ± 
1.3mV respectively. The AuNP-bacteriophage networks have a net negative charge. After the 
formation of BASP, both systems yielded similar negative zeta potentials meaning that the 
significant shift in zeta potential values occurred only during the formation of BASP 
containing S1MP(+). Morphological examination of the resulting systems by SEM confirmed 
this behavior. In agreement with the zeta potential data, SEM micrographs show more 
efficient association of AuNP-bacteriophage networks with S1MP(+) particles (Figure 16 
inset).” [83] 
  
Figure 16: Effect of surface zeta pote
of BASP and their components (inset) SEM image of BASP with S1MP(
showing better adhesion of AuNP
S1MP(-). Reproduced from [
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ntial of S1MP on BASP formation.
-bacteriophage networks to the S1MP(+) in comparison to 
83] with permission from The Royal Society of Chemistry
  Zeta potential 
-) and S1MP(+) 
. 
  
3.2.3
 
Evaluation of BASP contact angle
“Hydrophilicity measurements on
either S1MP(+) or S1MP(-) (Figure 
which can be important for avoiding non
system, as shown for nanovectors modified on their surface with hydrophilic polymers, such 
as PEG [116].” [83] 
Figure 17: Contact angle measurements of BASP
comparison to AuNP or AuNP
The Royal Society of Chemistry.
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 BASP showed that both types of BASP, containing 
17) are more hydrophilic than AuNP solution alone, 
-specific uptake by cells of the reticuloendothelial 
 showing an increase in hydrophilicity in 
-bacteriophage. Reproduced from [83] with permission from 
 
  
3.2.4
 
Spectral characteristics of 
“As mentioned above, the formation of 
monitored in real-time using UV
components of AuNP-bacteriophage networks in successive serial dilutions of the 
bacteriophage solution (5x10
reduction of UV-Vis absorbance at 530nm and simultaneous increase in the absorbance at 
NIR wavelengths between 650nm and 800nm.
absorbance occurs within 20sec of the addition of AuNP to bacteriophage.
bacteriophage with enhanced NIR absorbance are then pooled together and incubated with 
S1MP to form BASP. The increase of the absorban
following the formation of BASP (Figure 
Figure 18: UV-Vis spectra of BASP
in comparison with the same concentration of AuNP.
from The Royal Society of Chemistry.
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BASP 
AuNP-bacteriophage networks can be 
-Vis spectroscopy. Instantaneous interaction between the 
6
 TU/µL to 5x105 TU/µL) is indicated by the broadening and 
[105] This observed 3-4 fold increase in NIR 
ce in the NIR region was maintained 
18).” [83] 
 show 2-3 fold increase in the NIR absorbance of BASP 
 Reproduced from [83]
 
 The AuNP-
 with permission 
  
“The high absorbance in the NIR region enables the use of spectral properties of the 
systems for diagnostic and therapeutic purposes. As an example, use of SERS as a diagnostic 
tool was investigated and the NIR
AuNP is closely associated with bacteriophage and S1MP in BASP. The close association of 
AuNP to bacteriophage facilitated an 
the bacteriophage major coat proteins (such as phenylalanine and alanine)
presented in Figure 19 illustrates the enhancement of unique peaks, namely wavenumbers 
1022cm-1, 1001cm-1 and 995cm
associated with the BASP.” [
 
Figure 19: Detection of BASP using NIR
association with AuNP and S1MP.
Society of Chemistry. 
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-SERS spectra of BASP were recorded. As shown above, 
increase (~2000 fold) in the signature Raman peaks of 
-1[117; 118; 119], in the NIR-SERS spectra of bacterio
83] 
-SERS signal of bacteriophage in close 
 Reproduced from [83] with permission from The Royal 
. The data 
phage 
  
3.2.5
 
Heating efficiency of BASP
“We also investigated the NIR photothermal conversion proper
deionized water. When irradiated by a NIR laser the temperature in BASP increased by 10°C 
from room temperature within 10min while the AuNP did not heat up significantly (Figure 
20). The agglomerations of AuNP seen in BASP absorbed NIR photons 
in temperature increase. This heat generation triggered by NIR laser irradiation could 
potentially be used for thermal ablation.
 
Figure 20: Temperature as a function of NIR laser exposure time of AuNP and BASP
Reproduced from [83] with permission from The Royal Society of Chemistry.
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from lasers resulting 
” [83]  
ty of BASP in 
. 
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3.3
 
Loading efficiency of BASP 
3.3.1
 
Superparamagnetic iron oxide nanoparticles 
“Payload carrying capacity is another important consideration when designing 
nanovectors [59; 120]. In MSV, S1MP chemically modified on their surface have a 
significantly lower loading capacity of S2NP than unmodified S1MP, due to the 
unavailability of sufficiently open pores [75]. Here we evaluated the encapsulation efficiency 
of BASP by incorporating either amine functionalized SPION (15nm) or carboxylated QD 
(15nm). Post-assembly of AuNP-bacteriophage networks on the S1MP to form BASP retains 
the loaded SPION (1.17±0.34ng of iron/µg of silicon, i.e. ~100%) when compared to naked 
S1MP (Figure 21A). In contrast, ESTA-S1MP showed 70% lower loading (0.33ng/µg of 
silicon) similar to previously published study [75]. This demonstrates the ability of BASP to 
maintain the loading efficiency of S1MP while coupling targeted bacteriophage to their 
surface. This simple technique of coupling the targeting moiety to the vector enables both 
targeting as well as efficient payload delivery. NMR relaxometry data also corresponded to 
the loading efficiency, with SPION loaded S1MP exhibiting the shortest transverse relaxation 
time as shown in previous work.[78] Correspondingly, the r2 relaxivity (normalized to iron 
oxide concentration) of the SPION loaded BASP (162.09mM-1s-1) was half that of SPION 
loaded S1MP (258.75mM-1s-1) while that of SPION loaded ESTA-S1MP was significantly 
lower (98.63mM-1s-1) (Figure 21B). Conversely, the T2 relaxation times were short for 
SPION loaded S1MP and BASP (Figure 21C). The relaxation time of BASP (68.31msec) 
was almost twice as long as that of S1MP (39msec) but about 5 times shorter than that of 
ESTA-S1MP (354.4msec). These data show that BASP loaded with SPION maintain their 
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ability of exhibiting transverse relaxation and hence may be used for magnetic imaging 
applications.” [83] 
 
Figure 21: Loading of SPION into BASP. (A) Iron content analysis in S1MP, BASP and 
ESTA-S1MP following loading of SPION using the wet incipient method as quantified by 
ICP-OES; (B) Comparison of transverse relaxivity, r2 and (C) relaxation times, T2, of 
SPION loaded particles. Reproduced from [83] with permission from The Royal Society of 
Chemistry. 
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3.3.2
 
Quantum dots 
“Next we considered if loaded S2NP were closely associated with S1MP pores or 
were released from S1MP during BASP formation. QD loading into S1MP and BASP was 
comparable with 4.5±0.45ng of cadmium loaded in 1.5x108 silicon particles in both naked 
S1MP and BASP suggesting that QD were not lost during BASP formation. To determine if 
the QD escaped out of the S1MP and were trapped in the AuNP-bacteriophage networks, we 
visualized the systems using fluorescence microscopy. We would expect unassociated QD 
(Figure 22, green) to bind non-specifically to the AuNP-bacteriophage [121]. However, we 
observed specific localization of the QD (yellow due to co-localization) with S1MP (Figure 
22, red) and an absence of any non-specific staining outside the S1MP. AuNP-bacteriophage 
networks incubated with QD served as controls. We observed non-specific labeling of 
bacteriophage fibers (green) interspersed with AuNP (red dots).” [83] 
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Figure 22: Loading of quantum dots into BASP. Fluorescence microscopic images of QD 
(green) loaded S1MP and BASP (red) showing S1MP colocalization with QD (yellow). In a 
control experiment, free QD nonspecifically bound to AuNP-bacteriophage networks (arrow 
heads) enable the visualization of the bacteriophage fibers (green) while the AuNP appear as 
red dots. Reproduced from [83] with permission from The Royal Society of Chemistry. 
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3.3.3
 
BSA-FITC loading 
The macromolecule entrapment efficiency was measured by using a model protein 
molecule, fluorescently labeled albumin, and was determined to be highly efficient at 85-
90%. We used this compound to mimic the loading of the cytotoxic nanodrug, Abraxane® 
(albumin bound paclitaxel). Since BSA-FITC is a negatively-charged molecule, we loaded it 
into S1MP(+). It can be seen in Figure 14, that the loading process reverted the zeta potential 
of S1MP(+) from ~10mV to -30mV demonstrating high efficiency of encapsulation of the 
protein model. 
 
 
3.4
 
Biodegradation of BASP 
3.4.1
 
In vitro
 degradation 
“Degradation of the drug delivery system in biological fluids is an important 
characteristic that determines drug release kinetics as well as biocompatibility of the vector. 
We evaluated the degradation kinetics of BASP in simulated in vivo conditions such as 100% 
FBS at 37°C under constant motion. SEM micrographs (Figure 23A) and ICP-OES analysis 
(Figure 23B) show that the presence of AuNP-bacteriophage networks on S1MP in BASP 
does not affect the degradation kinetics of S1MP.  Quantification of the percentage silicon 
release by ICP-OES showed complete degradation of both S1MP and BASP within 24h, 
consistent with previously published work.[62] Although the degradation profile of BASP 
was not different from naked S1MP, the adhesion of serum proteins on particles was 
significantly decreased in BASP as seen by the open pores in BASP in contrast to the 
covered appearance of the naked S1MP (Figure 23A). This could potentially translate into 
  
the reduction of opsonization and hence non
vivo conditions (data not shown).
Figure 23: Time dependent degradation of S1MP and BASP in 100% FBS
micrographs showing the pattern of degradation of the porous silicon particles over time 
(Scale bar = 500nm); (B) ICP
percentage of total silicon content released from S1MP over time.
with permission from The Royal Society of Chemistry
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-specific uptake of particles by cells under 
” [83] 
-OES quantification of the degradation profile expressed as a 
 Reproduced 
. 
in 
. (A) SEM 
from [83] 
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3.4.2
 
In vivo
 integrity 
“Since the BASP is not a chemically conjugated assembly and is based on 
electrostatic interactions, which can be impaired in complex biological fluids (e.g. blood), it 
was important to verify the integrity of the systems following in vivo intravenous 
administration. We administered CRKL targeted BASP through the tail vein to orthotopic 
breast tumor bearing mice and analyzed tumor and liver tissue sections for the integrity of the 
systems in vivo. Tumor tissue from mice injected with BASP containing fluorescently 
labeled bacteriophage show co-localization of the bacteriophage (red) and S1MP (Figure 
24A). Similarly, immunohistochemistry staining for bacteriophage (Figure 24B, brown) in 
tumor tissue shows specific association with S1MP. Thus, we can infer that there is a close 
association of the bacteriophage and S1MP even after intravenous administration. 
Hyperspectral imaging provides unique reflectance spectral analysis of materials. Combined 
with dark field microscopy (Figure 24C(i)), hyperspectral imaging was used to identify the 
location of BASP. Once the particles were identified, spectra from different pixels on the 
particles were collected and grouped into libraries (S1MP and AuNP) (Figure 24C(ii)) 
according to the shape of the spectra. Mapping these libraries to the image of liver tissues 
shows co-localization of the silicon spectra and AuNP spectra (Figure 24C(iii)). The spectra 
collected for AuNP show a peak at approximately 650nm, which correlates with the red shift 
in the UV-Vis absorbance of BASP. These spectra based mapping confirm proximity of 
AuNP and S1MP and thus, the integrity of BASP.” [83] 
  
Figure 24: In vivo integrity of BASP.
injected intravenously with BASP. After a 4h circulation time, the animals were sacrificed 
and the tumor and liver were harvested and 
Fluorescence microscopy and (B) Immunohistochemistry analyses for bacteriophage show 
that the bacteriophage remains associated with S1MP and the assembly is not impaired in the 
circulation; (C) Hyperspectral images 
silicon and AuNP also confirming the close association of the AuNP and S1MP in the BASP.
Reproduced from [83] with permission from The Royal Society of Chemistry.
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 Mice bearing EF43.fgf4 mammary 
processed for histological analysis. (A) 
of the liver show superimposed spectral mapping of 
allografts were 
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3.5
 
In vitro
 targeting efficiency of BASP 
BASP are designed to enhance the targeting of S1MP to the tumor. We evaluated the 
specificity of binding of CRKL targeted BASP to breast cancer and endothelial cell lines 
under static and simulated flow conditions using various microscopic techniques and flow 
cytometry. 
3.5.1
 
Static conditions 
Figure 25 shows flow cytometry data of HUVEC and HMVEC incubated with S1MP, 
non-targeted fd-tet BASP and CRKL targeted BASP. It was observed that endothelial cells 
uptake silicon particles non-specifically. There was no statistical significance in the amount 
of CRKL targeted BASP uptake vs fd-tet BASP or S1MP uptake in both cell types.  
  
 
Figure 25: Association of BASP with cells 
cytometric data showing the percentage of 
HUVEC and (B) HMVEC. 
69 
in vitro under static conditions
endothelial cells associated with BASP; 
. Flow 
(A) 
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We also analyzed the mode of intracellular uptake by confocal and electron 
microscopy (Figure 26). MCF7 cells expressing the highest level of CRKL among the cell 
lines tested were used for these experiments. Confocal images demonstrate that CRKL 
targeted BASP are associated significantly more than the control groups to MCF7 cells. SEM 
micrographs show that after 6h of incubation some of the naked S1MP and control fd-tet 
BASP were associated with the cell surface. No internalization of S1MP by the breast cancer 
cell was observed in these experiments. In contrast, CRKL targeted BASP were internalized 
by breast cancer cells, indicating the specificity of uptake in the case of CRKL targeted 
systems. The timeline of internalization is significantly longer than in previous studies 
performed on endothelial cells where the cells start internalizing untargeted S1MP within 15 
min [115; 122]. This could be explained by the fact that the cells used in this study are of 
epithelial origin and are not considered as professional phagocytes.  
TEM has shown that the CRKL targeted BASP appear in a perinuclear 
vacuole/phagocytic vesicle. The system appears intact with AuNP surrounding S1MP 
hemispherical structure. This observation is important in light of the diagnostic potential of 
the system as the close proximity of AuNP and S1MP is essential for their detection using 
imaging techniques such as CT or NIR-SERS.  
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Figure 26: Association and internalization of BASP in MCF7 cells. (A) Confocal 
microscopy images showing enhanced association of CRKL targeted BASP (circles) 
compared to non-targeted controls (arrowheads). Green – S1MP, Red – Bacteriophage, Blue 
– Nucleus; (B) Scanning electron micrographs showing higher number of CRKL targeted 
BASP associated/cell when compared to the other two particle types; (C) Transmission 
electron micrograph showing perinuclear localization of CRKL targeted BASP. 
 
3.5.2
 
Effect of shear stress 
Particle margination and specific adhesion under shear stress was studied using 
Bioflux microfluidic channel plates, traditionally used for leukocyte adhesion and rolling 
analysis and platelet aggregation [123]. A schematic representation of the setup is shown in 
Figure 27A. It is comprised of a Bioflux 48 well interface, an inverted fluorescence 
microscope with a heated biological chamber and Bioflux 200 controller. The hydrodynamic 
conditions in the channel are controlled by the pneumatic pressure applied in the inlet and 
outlet wells of the channels. Figure 27B compares the number of particles adhering to cell 
monolayers in the presence and absence of endothelial cell activation at wall shear rates (S) 
of 10 s-1 (shear rate in tumor microvasculature) and 100s-1(shear rate in normal capillaries) 
[124; 125]. In contrast to the results in static conditions, it was observed that the number of 
CRKL targeted BASP adhering to both types of cells, HUVEC and HMVEC were 
significantly higher than fd-tet non-targeted or S1MP themselves at low shear rates of 10s-1. 
This difference is even more prominent (2-fold) in the case of HMVEC (microvasculature 
cells) when compared to HUVEC (normal endothelial cells).  As expected, at 100s-1, 
  
corresponding to shear rates in the 
to the cells was significantly reduced regardless of the activation condition of the cells or the 
targeting ability of the particles.
Figure 27: Effect of shear stress on the adhesion of CRKL targeted BASP to endothelial 
cells. (A) Schematic diagram of the set up showing Bioflux 200 
dimensions of the viewing channel and (B) Quantitative measurement of the number of 
particles adhered to endothelial cells after a flow for 
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normal microvasculature, the number of part
 
– 48 well flow chamber with 
1h at 10 and 100 s-1 shear rate
icles adhering 
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3.6
 
In vivo
 targeting efficiency 
To evaluate the tumor accumulation of BASP, 109 1.6µm hemispherical particles 
(S1MP, fd-tet BASP or CRKL targeted BASP) were injected via the tail vein into mice 
bearing orthotopic EF43.fgf4 tumors. Mice injected with PBS served as negative controls. 
The animals were sacrificed 4h after injection and the tumor was harvested for silicon 
content analysis by ICP-OES. Figure 28A shows the silicon content of S1MP, fd-tet BASP 
and CRKL targeted BASP in the tumor. The CRKL targeted BASP showed upto a 3 fold 
higher accumulation in the tumor tissue when compared to S1MP alone.  
Similar experiments using fluorescently labeled 1x0.4µm discoidal particles 
(108/mouse) were conducted and analyzed using intravital microscopy. Figure 28B shows 
representative images of particle accumulation in the tumor 1h after injection. The 
accumulation seen was mainly within the first few minutes, after which it leveled off. The 
number of particles accumulated in the tumor of mice injected with CRKL targeted BASP 
was almost 4 fold higher than the number of particles that accumulated in the other 2 
categories (Figure 28C). 
 
  
Figure 28: BASP accumulation in breast tumor models.
tissues as measured by ICP-
particle (red marked by arrows
(C) Semiquantitative analysis of the number of particles accumulated in the tumor as 
calculated from images captured at the end of the experiment.
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 (A) Silicon content in different 
OES; (B) Confocal images of tumor tissue showing enhanced 
) accumulation in the CRKL targeted BASP injected mice and 
 
  
The speeds of particles (1x0.4µm discoidal) injected during the intravital microscopic 
analysis were measured post acquisition 
The speeds of particles were orders of magnitude different for each case. The 
BASP travelled at speeds of about 10µm/s, while the fd
100µm/s and S1MP were the fa
 
Figure 29: Speed of particles flowing through the tumor vasculature
2D tracking module in NIS elements
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using 2D tracking module in NIS elements software. 
-tet non-targeted BASP were about 
stest at about 600µm/s (Figure 29). 
 as measured using 
  
CRKL targeted 
  
3.7
 
Therapeutic efficacy 
Figure 30 shows the antitumor response of BASP in EF43.
Mice were administered Abx, S1MP
(75mg/kg) twice a week. The Abx and S1MP
tumor size (mean final tumor volume 1.1cm
showed minimal increase (mean final tumor v
 
Figure 30: Therapeutic efficiency of Abraxane loaded BASP.
time following treatment with Abx, S1MP Abx or CRKL targeted BASP Abx.
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fgf4 tumor bearing mice. 
-Abx, fd-tet BASP-Abx or CRKL targeted BASP
-Abx treated mice showed marked increase in 
3), while CRKL targeted BASP-Abx treated mice 
olume 0.4 cm3). 
 Tumor size as a function of 
-Abx 
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3.8
 
CRKL as a soluble biomarker 
As mentioned earlier, a recent study showed that intracellular CRKL was secreted 
into the extracellular milieu in prostate cancer in vivo models (Mintz et al). Our results also 
confirmed the presence of CRKL on breast cancer cell lines as well as on endothelial cell 
lines. Based on these, we proposed that the “secreted” CRKL could be detected in both cell 
culture supernatants as well as the blood. For this purpose, we tested for the presence of 
soluble CRKL in cell culture supernatants, plasma from tumor bearing mice as well as 
plasma from clinical breast cancer patients using ELISA. 
3.8.1
 
Evaluation of soluble CRKL in in vitro and in vivo samples 
Conditioned media from cell culture supernatants and serum from breast tumor 
bearing mice were analyzed by ELISA for secreted CRKL. CM from human breast cancer 
cell line, SUM159, showed over a 20 fold higher CRKL concentration than that from normal 
breast epithelial cell line MCF10A (545±7 vs 26±5pg/mL, respectively) (Figure 31A). Mean 
serum levels of secreted CRKL from mice bearing human derived breast tumors were also 
significantly higher than control mice. In particular, mice grafted with patient derived tumors 
had about 13 fold higher serum levels of CRKL than control mice (486±130 vs 
37±21pg/mL), comparable to the results from in vitro studies (Figure 31B).  
3.8.2
 
Evaluation of soluble CRKL in clinical samples 
Soluble CRKL in sera from 29 breast cancer patients and 10 normal donors were 
measured by ELISA. The median CRKL concentrations in breast cancer patients’ sera were 
more than 1.4 fold higher than in healthy donors (4400±2560 vs 1860±1840 pg/mL, 
respectively, p<0.05). Patients with advanced clinical disease, i.e. stage 3 and 4, exhibited a 
2.8 fold (5300±2300pg/mL, p<0.005) increase in the serum CRKL concentration in 
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comparison to healthy donors (Figure 31C). Serum levels of CRKL were elevated from the 
median value in more than 90% of patients with advanced disease (T3 and T4) and in 100% 
of patients with metastatic disease. The sera from patients (n=4) who had not undergone any 
treatment had higher values than those patients who were undergoing treatment (5800±2000 
vs 3600±2700pg/mL, respectively, p= 0.13). 
 
 
  
Figure 31: Assessment of secreted CRKL levels in 
The CRKL concentration (CCRKL
bearing patient derived breast tumor 
using ELISA. 
80 
in vitro, in vivo and clinical samples
) was measured in (A) cell supernatant (B) serum from mice 
xenografts and (C) serum from breast cancer patients 
. 
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CHAPTER 4: DISCUSSION 
Nanovectors are increasingly used as therapeutic and imaging contrast agents in 
cancer due to their ability to bypass biobarriers and selectively accumulate in the tumor site 
[126]. An array of nanovectors has been developed with different features and functionalities 
over the last few years. While tumor-specific homing of the first nanoparticles took 
advantage of the disorganized and leaky vasculature of tumors and relied on passive 
accumulation due to the EPR effect, later nanovectors included more active targeting 
techniques such as conjugation of molecular recognition moieties, externally guided 
accumulation by magnetic focusing, etc. The addition of tumor targeting moieties onto the 
first generation nanovectors has its share of unpredictability depending on the affinity of the 
moiety to its target. If the affinity is very high, then the nanovectors bind very well to the 
cells that it first comes in contact with, such as the endothelium thereby limiting their ability 
to extravasate into the tumor [12].  It is not feasible for a single class of nanovectors to 
bypass all the sequential biological barriers and reach the tumor in significant quantities, 
irrespective of their geometry and targeting specificity. A third generation of nanovectors has 
been proposed that is designed to overcome the time-sequential biobarriers and deliver 
multiple payloads to the tumor specifically. These “multistage” nanovectors are an assembly 
of nanovectors nested within each other, each with unique functions [72].  
Physical characteristics, such as geometry of nanovectors have been recognized as 
important parameters that dictate their interaction with biological systems both at the cellular 
and vascular level [60; 127; 128]. Though size of nanovectors itself does not affect 
phagocytosis significantly, the shape has a great impact on their uptake by cells. This was 
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studied in macrophages, where, ellipsoidal particles were compared to spherical particles. 
Depending on the direction of interaction of ellipsoidal nanovectors and cells, a differential 
uptake was noticed. On the other hand, phagocytosis of spherical particle were mostly 
uniform due to  its symmetry [129]. Vascular interactions have also been linked to size, 
shape and density of particles mathematically and experimentally. Under shear flow, 
discoidal particles exhibited higher adhesion to endothelial cells than spherical particles [127; 
130]. Based on these mathematical models, our lab designed non-spherical porous silicon 
microparticles that serve as first stage particles (S1MP) in multistage vectors. The S1MP are 
designed to facilitate their preferential concentration on tumor vasculature and the encasing 
of second stage nanoparticles (S2NP). The S2NP which in turn carry therapeutic or imaging 
agents are released into the tumor.  
The S1MP are fabricated using photolithography and can be tailored to produce 
various geometries of particles, ranging from discoidal to hemispherical to cylindrical. The 
pore size and porosity can be tuned by electrochemical etching according to requirements. 
The pore sizes range from 5nm to 120nm in diameter [69]. Various studies with these 
particles have been conducted. S2NP, such as SPION [78], quantum dots [59], gadolinium 
nanotubes [80], paclitaxel containing micelles [79], liposomes [77] and hollow gold 
nanoshells [81] have been loaded into these particles. The surface of the S1MP has been 
decorated with peptides [74], thioaptamers [75], biomimetic leukocyte membrane [76] and 
agarose [24] to either facilitate tumor homing or lysosomal escape or avoid immune 
recognition.  
While the above studies have demonstrated the successful loading and conjugation of 
targeting moieties independently, combining the two efficiently have been a challenge. The 
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design of nanovectors governs their accumulation at a specified site. The design parameters 
include size [131], shape [132; 133; 134], surface charge [135; 136; 137] and deformability 
[138]. Another important parameter is the surface decoration with targeting ligands specific 
to the disease microenvironment [139; 140].Typically, the addition of molecular targeting 
ligands on nanovector surfaces involve covalent conjugation chemistry that may impair the 
targeting ability of the biological entities as well as reduce the volume of pores available for 
loading active substances, in the case of porous drug carriers.  
In this study, we demonstrate a simple method to immobilize molecularly targeted 
bacteriophage on S1MP without compromising its payload carrying potential. 
Immobilization of bacteriophage on various surfaces has been performed for use as 
antibacterial agents/surfaces [141]. However most of these reports use either 
covalent/chemical conjugation techniques or genetic modifications for the immobilization. 
These processes, as described above can be detrimental to the drug carrier or can be 
complicated and time consuming. We proposed the use of electrostatic interactions to 
assemble BASP, by co-incubation of S1MP, bacteriophage and AuNP. Since the formation 
of these electrostatic interactions is spontaneous, we were able to load  the S1MP with S2NP 
and instantaneously cover with the AuNP–bacteriophage networks, thus avoiding loss of 
loaded S2NP. 
Among the physical parameters involved in designing BASP, we studied the effect of 
shape, size, surface potential and porosity on the BASP formation. It was observed that shape 
and size of S1MP did not have an effect on the formation of BASP. However, the  
association of AuNP  with S1MP was evidently better with positively charged, porous 
particles than their association with non-porous silica beads or negatively charged particles. 
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The porosity of particles provides an increased surface area with more sites for the 
interaction of the bacteriophage with the particles. This observation that porosity of S1MP 
enhances the adhesion of AuNP–bacteriophage networks is in agreement with previous 
studies on the effect of particle porosity on the efficiency of surface adsorption [142]. 
While positively charged nanovectors have greater efficiency in cell membrane 
penetration and internalization, compared to negatively charged particles, they also elicit 
more immune responses when in circulation [143]. On the other hand, negatively charged 
particles are better at avoiding recognition by the immune system. Our observation that 
positively charged S1MP form BASP more efficiently also has the advantage that the final 
BASP formed has a net negative charge and thereby could potentially avoid recognition by 
the immune system. Further, the negative charge might help in avoiding non-specific 
internalization of the BASP, allowing them to release S2NP into the tumor 
microenvironment. 
The formation of BASP is characterized by a red shift in the UV-Vis absorbance of 
AuNP from around 530nm to 710nm explained by dipole-dipole interactions between AuNP 
when the interparticle distance becomes lesser than its diameter [109]. However, this red 
shift occurs at very specific ratios of bacteriophage and AuNP. At higher ratios of 
bacteriophage to AuNP, the placement of AuNP on bacteriophage is sufficiently large to 
avoid dipole-dipole interactions. In contrast, at lower ratios, the concentration of 
bacteriophage is very dilute and hence, majority of the AuNP are still in colloidal form and 
do not interact with each other. Thus, it is important to achieve a delicate balance in the 
relative concentrations of phage and AuNP during formation of the networks. 
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Red-shift in UV-Vis absorbance corresponds to an increase in the NIR absorbance. 
This can be used to advantage because most deep tissue imaging utilizes this NIR window  
(650-900nm), where hemoglobin is transparent [144], to discern function, localization, 
affinity and fate of nanovectors through their innate scattering properties [145]. Here we 
demonstrate that non-invasive, longitudinal imaging techniques such as NIR-SERS can be 
used to provide critical information at the molecular scale in real-time. Fingerprints of BASP, 
that appear when bacteriophage and S1MP are in close association with AuNP, can be used 
as signal reporters for monitoring the formation and presence of BASP. These photonic 
properties of BASP originating from the quantum confinement of AuNP in BASP are tunable 
based on the design of the system and offer a direct ability to assess their interaction within 
biological systems, providing diagnostic capability [83]. 
 As discussed above, one of the major requirements of a good nanovector is high 
payload carrying capacity. However chemical conjugation of targeting moieties frequently 
hampers this feature [75]. Here, we demonstrated that S1MP retain their payload carrying 
capacity even after the incubation with AuNP-bacteriophage networks to form BASP. Solid 
nanoparticles such as SPION and quantum dots as well as protein molecules such as BSA-
FITC (model drug molecule) were loaded into the S1MP successfully. This simple technique 
of coupling the targeting moiety to the nanovector enables both targeting as well as efficient 
payload delivery.  
Having shown the efficient payload encapsulation, we studied the targeting ability of 
BASP. In our study, we hypothesized that an intracellular adaptor protein, CRKL, secreted 
by tumor cells into the microenvironment would bind to the extracellular domain of integrins 
on both tumor cells as well as endothelial cells’ surface. We proposed that this extracellular 
 86 
 
CRKL can serve as a good target for homing nanovectors to the tumor site. To confirm our 
hypothesis, we evaluated the surface localization of CRKL in endothelial cells and breast 
cancer cells. While only a small percentage of endothelial cells were positive for surface 
CRKL, incubation with cancer cell CM, increased the surface localization of CRKL. We also 
showed that CRKL is secreted from tumor cells into the cell culture supernatant. Thus, the 
enhanced CRKL in CM treated endothelial cells could be the soluble CRKL secreted by 
cancer cells. Further, in vivo allografts showed colocalization of CRKL in endothelial cells, 
suggesting that CRKL in these endothelial cells can act as a target for nanovectors. We also 
detected an increased surface-bound fraction of CRKL in various breast cancer cell lines 
when compared to non-cancerous epithelial cell lines. Immunofluorescence staining of breast 
cancer cell lines revealed CRKL on both the cell surface as well as in the intracellular 
compartments.  
In accordance with in vitro studies, CRKL was over-expressed in tumor sections 
(Figure 11). Although immunohistochemical staining is not specific for surface-bound 
CRKL, it is in agreement with previously published data that CRKL is over-expressed in 
various tumor models, including gastric carcinomas [95], head and neck squamous cell 
carcinomas [146] and lung carcinomas [97]. Recent work by Zhao et al has shown that 
CRKL is over-expressed in 37% of breast cancer samples studied and was correlated with 
progression and malignant proliferation [100]. Our results provide further evidence that 
tissue expression of CRKL can serve as a potential tissue biomarker for breast tumors.  
Moreover, we anticipate that in addition to the use of CRKL as a molecular target, 
membranal presence of the protein on the surface of endothelial and tumor cells can 
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serve as selective target to direct nanoparticle based therapeutics and diagnostics to the 
tumor. 
Thus, we used extracellular CRKL targeted, genetically engineered bacteriophage 
expressing a peptide sequence, YRCTLNSPFFWEDMTHECHA, homologous to the plexin-
semaphorin integrin domain of β1 integrins in the formation of BASP. This phage has been 
shown to be as effective at targeting prostate tumor cells as the more commonly used RGD 
peptide [92]. Here we tested the efficiency of CRKL targeted phage to bind endothelial cells. 
CRKL targeted BASP were compared to S1MP and fd-tet non-targeted BASP. Our data 
showed that there was no significant differences in the association of CRKL targeted BASP 
to endothelial cells when compared to the other two particle types in vitro under static 
conditions. This is in correlation with data previous published on endothelial cells [115]. 
Endothelial cells act like professional phagocytes and uptake nanoparticles non-specifically. 
We also tested the efficiency of uptake of CRKL targeted BASP in breast cancer cell line, 
MCF7, that has a significant amount of CRKL on its surface. In this case, we could see a 
significant enhancement in the association/uptake of CRKL targeted BASP through specific, 
probably receptor mediated, interactions with the epithelial cell line as evidenced by the 
presence of BASP inside a vesicle when internalized (Figure 26C). 
In contrast to targeting experiments under static conditions, our results from 
experiments conducted under shear stresses, capitulate better the observed behavior in vivo. 
For example, we saw that the number of CRKL targeted BASP associated with endothelial 
cells under low shear stress, such as that seen in tumor microcirculation, was twice as much 
as non-targeted fd-tet BASP or S1MP. This is due to the formation of strong interactions 
between CRKL on the surface of endothelial cells and the peptide expressed on 
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bacteriophage coat proteins. In the case of S1MP and fd-tet BASP, although they probably 
experience similar hemodynamic flow conditions, they do not form strong bonds by means of 
receptor-ligand interactions. Thus, the hemodynamic forces dislodge the particles before they 
can form a firm bond with the endothelial cells. As a result, more CRKL targeted BASP 
remain adhered to the cells than non-targeted particles. On the contrary, at higher shear rates 
of 100s-1(healthy microvasculature) the forces are much higher and thus the likelihood of 
particle adhesion is reduced. At these shear rates, the presence of targeting moieties on the 
particle surface did not make a significant difference in the binding of particles to endothelial 
cells, thereby suggesting that addition of targeting moiety onto the S1MP enhances the 
binding of particles to only tumor microvasculature and not to healthy microvasculature. 
When evaluating the systems in vivo, we observed that the changes were significantly 
enhanced when compared to in vitro conditions. For example, the number of CRKL targeted 
BASP bound to the tumor in in vivo allografts was 4-fold higher than non-targeted particles. 
Also, the speeds of particles were orders of magnitude different for each case. The CRKL 
targeted particles travelled at speeds of about 10µm/s, while the fd-tet BASP were about 
100µm/s and the S1MP were the fastest at about 600µm/s. This apparent difference between 
the in vitro and in vivo studies could be attributed to the differences in conditions. For 
example, in vivo flow involves not only specific shear rates, as is considered in in vitro 
studies, but also has very tortuous vasculature and whole blood containing multicellular 
components, all of which can affect the hemodynamics of blood flow. 
Finally, we evaluated if this targeted system could efficiently carry therapeutics to the 
tumor site. For this, we injected tumor bearing mice with Abraxane loaded BASP and 
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compared their effect to either Abraxane itself or Abraxane loaded S1MP. We found that the 
targeting of the BASP significantly enhanced their therapeutic efficiency. 
CRKL as a serum biomarker 
In breast tumors, the majority of clinically used biomarkers are proteins over-
expressed in tissue, which can be detected histologically in specimens from biopsies or 
following tumor resection. Their expression prescribes various treatment settings and is 
correlated to disease prognosis [147], particularly in the early disease stages. One of such 
biomarkers, c-erbB2, led to the discovery of trastuzumab [148]. However, the necessitation 
of invasive biopsies is a drawback that may be addressed by the detection of soluble 
biomarkers in body fluids. Overexpressed and secreted proteins from cancer cells, detected in 
the sera of cancer patients, are easy to collect and have been used clinically as diagnostic and 
prognostic markers for cancers [149]. A few examples of secreted proteins used for cancer 
diagnosis include prostate specific antigen for prostate cancer [150], carcinoembryonic 
antigen CA125 for ovarian cancer [151] and cytokine colony stimulating factor-1 (CSF-1) 
[152] for endometrial carcinoma. A few soluble biomarkers for breast cancers include CA 
15.3 and CA 27.59 and vascular endothelial growth factor (VEGF) which have shown to be 
of prognostic value and are being evaluated in conjunction with diagnostic imaging to 
monitor metastatic diseases during the course of therapy [147].   
In this study, we propose that CRKL, generally considered as an intracellular protein, 
can serve as a soluble biomarker for breast tumors. It is generally agreed that intracellular 
signaling of CRKL is involved in tumor progression of various tumor types, however, the 
role of soluble (secreted) fraction of CRKL have not been explored. For this purpose, we 
analyzed in vitro, in vivo and clinical samples to evaluate if the soluble fractions of CRKL 
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can be detected in cell culture media and blood serum. Our results showing significantly 
higher levels of soluble CRKL in serum from breast tumor xenograft bearing mice and breast 
tumor patients to healthy donors, suggest the use of CRKL as a soluble biomarker. The most 
widely used clinical breast cancer biomarker, CA 15.3, serves as a prognostic marker, to 
monitor response of breast cancer to treatment or detect early relapse [153]. However, CA 
15-3 is elevated in only 3% of patients with localized early stage cancer and upto 70% of 
patients with metastatic disease [154]. In our study, we found that 100% of patients with 
metastatic disease have elevated serum levels of CRKL. Thus, soluble CRKL might serve as 
a stronger biomarker for predicting metastasis. Further, among patients analyzed in this 
study, four had not undergone treatment and had mean values 1.6 fold higher than the rest of 
the patients (n=25) who were undergoing treatment. Albeit the small sample size, this clear 
trend with a p-value of 0.13, suggests that CRKL levels might also be useful in monitoring 
treatment of breast cancer and requires further evaluation in larger sample size or progressive 
clinical studies.  
CONCLUSIONS AND FUTURE DIRECTIONS 
In this study we report a strategy for non-covalent attachment of targeting entities to 
porous silicon particle surfaces, which enables independent control over the loading of 
actives into the porous structure of the particles and their targeting to elements in the tumor 
microenvironment. The attachment of AuNP-bacteriophage networks on the S1MP surface 
does not impair the loading capacity of naked S1MP. The resulting BASP are biodegradable 
in serum and maintain their integrity while injected intravenously. This shows that 
electrostatic interactions of components in the system are stable under constant motion as 
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well as in vivo. We demonstrated that extracellular CRKL (traditionally thought of to be an 
intracellular protein) served as a very good target for efficient tumor directed accumulation 
of BASP and subsequently improved therapeutic effect on breast cancer allograft models.   
We have also revealed that high levels of secreted CRKL can be detected in the 
plasma of breast tumor bearing mice and breast cancer patients. To the best of our 
knowledge, this is the first report about the possibility to detect soluble fractions of CRKL in 
body fluids from cancer patients. The results of our study suggest that CRKL can be used as 
a soluble serum biomarker in breast cancer patients especially in the advanced disease stages.  
The BASP has more applications that haven’t been studied to its full potential, for 
example, the applications related to the optical properties of AuNP in BASP, such as NIR-
SERS imaging and detection in vivo and thermal ablation of tumors using NIR lasers. These 
BASP also present multiple opportunities for future research and improvement. The 
bacteriophage in BASP can be easily replaced with bacteriophage displaying any other 
targeting peptide of choice. Based on the targeting moieties chosen, BASP can also be 
evaluated for use in inflammatory conditions and cardiovascular diseases. Further, the S2NP 
can themselves be decorated with a targeting moiety or other surface decorations that can be 
used to overcome additional barriers, such as facilitation of lysosomal escape or subcellular 
organelle targeting, thereby providing a “two-fold” targeting of the nanovector, i.e. tumor 
targeting by the S1MP and cellular targeting by the S2NP.  
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